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US 9, 186,302 B2 
1. 
BOMATERAL COMPOSITIONS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is based on and claims priority to U.S. 
Non-Provisional Application Ser. No. 61/456,045 filed on 
Oct. 29, 2010, which is hereby incorporated herein by refer 
CCC. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
This invention was made with government Support under 
Department of Defense/USA Medical Research AQCAward 
No. W81XWH. The government has certain rights in the 
invention. 
FIELD OF THE INVENTION 
This invention relates in general to compositions of matter 
and more particularly, to compositions useful as biomaterials. 
The compositions comprise organosilicon monomers (pref 
erably silorane monomers) and chemical curing systems or 
dual chemical/light curing systems. The compositions may 
include one or more tetraoxaspiro5.5undecanes (“TOSUs) 
and/or fillers. Photoacids, photosensitizers and/or a reaction 
promoters (electron donors) may also be included in the com 
position. The polymerizable compositions of the present 
invention are useful for a variety of applications, including 
use as biomaterials, for example as bone cements, bone sta 
bilizers, dental composites, crowns, and the like. 
DESCRIPTION OF RELATED ART 
Bone fractures are suffered by nearly six million Ameri 
cans each year. The common methods for fracture stabiliza 
tion Such as casts, splinting, intramedullary pinning, and 
external fixation, do have their drawbacks especially with 
regards to stabilization of Small and growing bones. In addi 
tion to hampering soft tissue management, splinting cannot 
adequately stabilize highly unstable fractures or injuries with 
considerable bone loss. There must be sufficient bone cortex 
to support pin stabilization, especially with epiphyseal (near 
the end of the bone) fractures. These fractures lacking suffi 
cient cortex often require pin placement across the adjacent 
joint leading to joint stiffness. Fractures in children can be 
further complicated by rapid growth of bone, thus requiring 
continual adjustment of the stabilization technique. 
Frequently, bone cement has been used to stabilize frac 
tures. The current bone cements are methacrylate based sys 
tems packaged in two components. The powder contains a 
mixture of polymethyl methacrylate (“PMMA'), methyl 
methacrylate-styrene-copolymer, and a radio opacifier (either 
barium Sulfate or Zirconium oxide). The second component is 
a liquid monomer typically containing methyl methacrylate, 
N,N-dimethyl-p-toluidine, and hydroquinone. The cure time 
of commercially available PMMA bone cements ranges from 
6 to 22 minutes, and reaches a peak exotherm from 75 to 110° 
C. Thermal finite element models have found temperatures in 
excess of 60° C. at the bone cement and cancellous bone 
interface. The fracture toughness of bone cements generally 
ranges from 1.0 to 1.5 MPalm’. Flexural strength of bone 
cements ranges from 60 to 75 MPa and flexural modulus is 
between 2.2 and 3.3 GPa. Bone cements typically have a 













meet or surpass the requirements described in ISO 5833 
Implants for Surgery—Acrylic Resin Cements. 
PMMA was first used in orthopedic surgery by Sir John 
Charnley for total hip arthroplasty in 1970 and the current 
formulation is essentially unchanged. Bone cement has dif 
ferent properties than other PMMA resins, due to both its 
additives and how it is prepared. Although the fully polymer 
ized form of PMMA has good compatibility with human 
tissue, there are several drawbacks to its use. The monomer 
component is antigenic and induces severe toxicity, contrac 
tion with polymerization, and intense heat generation. These 
cements are highly exothermic, and have been shown to cause 
thermonecrosis in animal models. Bone cement typically has 
Voids due to Volatilization of the monomer during polymer 
ization, which results in a porosity of 3 to 11%. Pressurization 
of the resin, as occurs during implantation of a femoral bone, 
can raise the boiling point of the monomer and decrease pore 
formation and size, but can be problematic if air is carried into 
the resin during implantation. The volume contracts by 5-7% 
during polymerization. This causes internal pores which can 
serve as crack initiators. The heat generated is determined by 
thickness/weight of resin, with a peak temperature rise in the 
range of 75-85°C. Although PMMA is biologically compat 
ible, the monomer is an irritant and possible carcinogen. 
Unreacted residual monomer, approximately 3% after one 
hour, is present in the hardened polymer and can affect 
strength while leaching out into tissues, potentially causing 
hypotension, a common problem which can lead to possible 
cardiopulmonary events. The bone-resin interface is achieved 
by mechanical interlock, because the PMMA has no inherent 
adhesive properties. Dense bone causes less resin penetration, 
which can be an issue for resin fixation in younger patients 
Such as military recruits whose bone structure may have less 
trabecular porosity. Use of bone cement in hip arthroplasties 
has also been shown to increase systematic levels of gamma 
glutamy transperptidase (“GGTP), which can result in anor 
exia and nausea/vomiting. Other drawbacks to the use of 
PMMA-based cements include lack of bioactivity, volumet 
ric shrinkage upon polymerization, toxicity of the activator 
(N,N-dimethyl-p-toluidine) and possible involvement of the 
radiopacifier in third body wear. Therefore, it would be desir 
able to provide an alternative bone cement to PMMA-based 
Cement. 
BRIEF SUMMARY OF THE INVENTION 
The present invention is directed to biomaterial composi 
tions, as well as methods for manufacturing the same, and 
methods of using the compositions. The biomaterial compo 
sition comprises one or more organosilicon monomers (such 
as a silorane) and a chemical curing system or dual chemical/ 
light curing system for polymerizing the monomer(s). The 
compositions may include one or more tetraoxaspiro5.5 
undecanes (“TOSUs) and/or fillers. Accelerators (such as 
photoacids), photosensitizers, and/or electron donors may 
also be included in the composition as appropriate. 
The biomaterial compositions of the present invention are 
comparable to or superior to conventional PMMA systems in 
many characteristics. For example, in one aspect of the 
present invention, the compositions of the present invention 
exhibit significantly less polymerization stress without an 
associated proportional reduction in mechanical properties. 
In another aspect of the present invention, the biomaterial 
compositions exhibit enhanced biocompatibility and reduced 
cytotoxicity and genotoxicity. In general, the compositions of 
the present invention will not generate the cytotoxicity, anti 
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genicity, polymerization stress, and heat generation that are 
characteristic of conventional PMMA bone cements. 
In another aspect, it is anticipated that the biomaterial 
compositions of the present invention exhibit a peak exo 
therm below 50° C., more preferably below 45° C. For 
example, the silorane-based compositions of the present 
invention may exhibit a peak exotherm below about 49, 48, 
47, 46, 45, 44, 43,42, 40,39,38, 37, 36,35,33, 32, 31, or 30° 
C. Most preferably, the peak exotherm is within 1, 2, 3, 4, or 
5°C. of the body temperature of the patient. For example, the 
P1 system (chemical curing system) and P2 systems (dual 
chemical/light curing system) described herein typically 
exhibit a peak exotherm of about 25 to 30°C. As such, it is 
anticipated that the biomaterial compositions of the present 
invention will not cause thermal necrosis. 
The low exotherm of the chemically or dual cured silorane 
biomaterial (about 25- to 30°C.) compared to commercially 
available bone cement (about 70 to 90° C.) is an important 
property of the compositions of the present invention. Many 
antimicrobial agents and growth factors exhibit heat sensitiv 
ity. For example, proteins are degraded or denatured with 
increasing heat leading to inactivation or conversion to com 
pounds with potential toxicity. Even antimicrobial agents 
such as silver (though relatively heat insensitive) may exhibit 
Some heat sensitivity in certain crystalline forms. Impor 
tantly, conventional bone cements have not included growth 
factors (such as bone morphogenetic protein 2) due to their 
thermal instability. See Prountos et al., The effect of antibiot 
ics on bone healing current evidence, Expert Opin Drug Saf. 
10935-945 (2011); Yano et al., Osteoinductive capacity and 
heat stability of recombinant human bone morphogenetic 
protein-2 produced by Escherichia coli and dimerlized by 
biochemical processing, J Bone Miner Metab 17 355-363 
(2009); and Landry et al., The kinetics of thermal instability in 
nanocrystalline silver and the effect of heat treatment on the 
antibacterial activity of nanocrystalline silver dressings, Bio 
materials 30 6929-6939 (2009). With the lower exotherm of 
the silorane biomaterial compositions of the present inven 
tion, antimicrobials and growth factors (such cartilage or 
bone growth factors, e.g., cartilage-derived morphogenic pro 
teins or bone morphogenic proteins) should remain stable. In 
one aspect, the biomaterial composition contains growth fac 
tors selected from the group consisting of TGFB1, TGFB2, 
TGFB3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, 
BMP-8, BMP-9, CDMP-1, CDMP-2, or CDMP-3. 
In another aspect, the biomaterial compositions of the 
present invention exhibit flexural strength greater than about 
20 MPa, and preferably greater than about 50 MPa. For 
example, the flexural strength may be greater than about 20, 
30, 40, 50, 55, 60, or 65 MPa (or have a value of some range 
therebetween), with higher flexural strengths being preferred. 
For example, the P1 system (chemical curing system) typi 
cally exhibits a flexural strength of about 22 to 33 MPa, and 
the P2 systems (dual chemical/light curing system) described 
herein typically exhibit a flexural strength of about 25 to 60 
MPa. 
In another aspect, biomaterial compositions of the present 
invention exhibit a flexural modulus greater than 1.5 GPa. For 
example, the flexural modulus may be greater than about 1.5. 
1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 
3.8, or 4.0 GPa (or have a value of some range therebetween). 
For example, the P1 system (chemical curing system) typi 
cally exhibits a flexural modulus of about 1.5 to 1.7 GPa, and 
the P2 systems (dual chemical/light curing system) typically 
exhibit a flexural strength of about 2.2 to 3.5 GPa. 
In another aspect, the biomaterial compositions of the 













minutes (e.g., 5, 6,7,8,9, 10, 11, 12, 13, 14, or 15 minutes (or 
Some range therebetween), and preferably no longer than 20 
minutes, when measuring the period of time required for the 
compositions to harden or “set according to the Gillmore 
Needle Test (ASTM C266-89). For example, the P1 system 
(chemical curing system) and P2 systems (dual chemical/ 
light curing system) described herein typically exhibit a han 
dling time of about 8 to 10 minutes. 
Therefore, the present invention is directed to a biomaterial 
composition which is an alternative to PMAA based bone 
cements. For example, an ideal bone cement composition will 
(1) provide a time-efficient means of reducing even Small 
bone fragments to anatomically correct positions; (2) have the 
same loading response as natural bone; (3) be biocompatible; 
(4) possess the handling properties to allow for the Surgeon/ 
technician to Successfully place the material in the fracture 
site in a controlled manner, and/or (5) not to integrate with the 
bone, but be easily removed without significantly destroying 
the tissue. It is anticipated that the biomaterial compositions 
of the present invention will have one or more of these prop 
erties, and preferably all of these properties. 
The biomaterial compositions may be used as a bone and 
dental cement, bone filler, bone anchor, and bone graft in 
patients. For example, potential applications for the bioma 
terial composition include, but are not limited to bone cement 
(the adhesive or material used to join bone fragments together 
or for placement and anchorage of prosthetic devices); 
replacement of cartilage found in joints, e.g., knee meniscus, 
temporomandibular joint, wrist, etc.; Vertebroplasty (the aug 
mentation or mechanical support of a compromised verte 
brae); bone filler (the material that fills cavities in bone either 
permanently or temporarily as new bone fills in the defect): 
bone scaffold; adjunct to metal cages for spinal fixation with 
screws (the biomaterial may provide additional mechanical 
Support); and Support of fractures to non-weight bearing 
bones (e.g., the orbital bones of the face; and prosthetic spinal 
disc nucleus). The biomaterial compositions of the present 
invention may also be used for the delivery of heat sensitive 
agents—including heat-sensitive antimicrobials and growth 
factors—due to its low exotherm. For example, the biomate 
rial compositions—combined with a heat-sensitive antimi 
crobial or growth factor—maybe in the form of a spacer, or as 
beads or in another vehicular form. 
Additional aspects of the invention, together with the 
advantages and novel features appurtenant thereto, will be set 
forth in part in the description that follows, and in part will 
become apparent to those skilled in the art upon examination 
of the following, or may be learned from the practice of the 
invention. The objects and advantages of the invention may be 
realized and attained by means of the instrumentalities and 
combinations particularly pointed out in the appended 
claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows cell growth responses of MLO-A5 cells for 
chemically cured silorane resins (DCA, DCB, DCC) com 
pared to the light cured silorane resin (PIH) after culturing 
resins with cells for 24 and 48 hours. Panels a-d are from 
Trypan blue data and panels e and fare from MTT data. The 
asterisk (*) defines significantly different values (p<0.05) 
from the light cure silorane (PIH). 
FIG. 2 shows that the in vitro biocompatibility of the 
chemical cure silorane resin (SilMixCC) is comparable to the 
light cure silorane resin (SilMix LC) as demonstrated by the 
US 9, 186,302 B2 
5 
similar number of live and dead adherent and non-adherent 
cells counted after 24 and 48 hours incubation with MLO-A5 
cells. 
FIG. 3 shows that the ultimate load to fracture of excised 
mouse femora is similar when stabilized with either photo 
initiated or dual chemical/light cured silorane resin. 
FIG. 4 shows the chemical and dual chemical/light cured 
silorane stress and modulus measurements. Panels a and b 
illustrate the flexural strength and flexural modulus of the P1 
and P2 systems compared to conventional PMMA systems. 
Panels c and d illustrate the flextural strength and modulus of 
two exemplary P1 systems. Panele illustrates the stress-strain 
curve for an exemplary neat dual chemical/light cured system 
comprising acetic acid, PIH, and camphorquinone. 
FIG. 5 shows the exotherm temperature data for photoini 
tiated and chemically initiated silorane resins. These results 
show that the photoinitiated silorane has a much higher exo 
therm (127°C.) than the chemically initiated (40° C.). The 
chemically initiated silorane also has a longer curing time. 
Note that the curing time presented for the chemical cure does 
not take into account the additional one minute of mixing. 
FIG. 6 is photographs of the silorane bone cement mimics. 
The first sample (BCM 1/2) did not mix well and formed a 
gritty clump of material. However, samples BCM 3/4 and 
BCM5/6 were much smoother and polymerized with a glossy 
finish. 
FIG. 7 is an exotherm profile of six exemplary biomaterial 
compositions in accordance with the present invention. 
BRIEF DESCRIPTION OF PREFERRED 
EMBODIMENT 
In the following description, certain details are set forth 
Such as specific quantities, sizes, etc. So as to provide a thor 
ough understanding of the present embodiments disclosed 
herein. However, it will be obvious to those skilled in the art 
that the present disclosure may be practiced without such 
specific details. In many cases, details concerning Such con 
siderations and the like have been omitted inasmuch as Such 
details are not necessary to obtain a complete understanding 
of the present disclosure and are within the skills of persons of 
ordinary skill in the relevant art. 
The terms “comprises.” “comprising.” and variations 
thereof do not have a limiting meaning where these terms 
appear in the description and claims. 
The recitation herein, of numerical ranges by endpoints is 
intended to include all numbers subsumed within that range 
(e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5). 
As used herein, “a” or 'an' means “at least one' or “one or 
more' unless otherwise indicated. In addition, the singular 
forms “a,” “an and “the include plural referents unless the 
content clearly dictates otherwise. Thus, for example, refer 
ence to a composition containing "a compound includes a 
mixture of two or more compounds. As used in this specifi 
cation and the appended claims, the term 'or' is generally 
employed in its sense including “and/or unless the content 
clearly dictates otherwise. 
Unless otherwise indicated, all numbers expressing quan 
tities of compounds, measurement of properties, and claims 
are to be understood as being modified in all instances by the 
term “about. Accordingly, unless indicated to the contrary, 
the numerical parameters set forth in the foregoing specifica 
tion and attached claims are approximations that can vary 
depending upon the desired properties sought to be obtained 
by those skilled in the art utilizing the teachings of the present 
invention. At the very least, and not as an attempt to limit the 














claims, each numerical parameter should at least be construed 
in light of the number of reported significant digits and by 
applying ordinary rounding techniques. Notwithstanding that 
the numerical ranges and parameters setting forth the broad 
Scope of the invention are approximations, the numerical 
values set forth in the specific examples are reported as pre 
cisely as possible. Any numerical value, however, inherently 
contains certain errors necessarily resulting from the standard 
deviations found in their respective testing measurements. 
As used herein, the term "patient' encompasses humans 
and domestic animals including pets and farm animals, exotic 
animals as found in Zoos and similar preserves, and research 
animals as used in public and private research institutions, 
e.g., monkeys, chips, cats, dogs, horses, pigs, sheep, cows, 
monkeys, rats, mice, guinea pigs, and rabbits. 
As used herein, the term “chemical cure” refers to a cata 
lytic system capable of catalyzing them polymerization of the 
organosilicon monomers (preferably silorane monomers) 
described herein independent of light. While the chemical 
cure system may optionally include one or more components 
of a light initiation system (e.g., PIH), the chemical cure 
system is capable of polymerizing the organosilicon mono 
mers (preferably silorane monomers) in the dark. 
As used herein, the term "dual' curing system means and 
refers to a system that cures at least partially by light-cure 
(electromagnetic radiation) and at least partially by a chemi 
cal cure. As discussed more fully below, the dual chemical/ 
light curing system may contain on or more accelerators, 
photosensitizers, and/or reaction promoters. Light (typically 
ultraviolet, visible, or infrared) is needed in order for the 
complete curing to occur. 
Molecular terms, when used in this application, have their 
common meaning unless otherwise specified. It should be 
noted that the alphabetical letters used in the formulas of the 
present invention should be interpreted as the functional 
groups, moieties, or substituents as defined herein. Unless 
otherwise defined, the symbols will have their ordinary and 
customary meaning to those skilled in the art. 
The term “alkyl embraces a branched or unbranched satu 
rated hydrocarbon group of 1 to 12 carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl. n-butyl, isobutyl, t-butyl, 
octyl, decyl, tetradecyl, as well as cyclic alkyl groups and the 
like. 
The term “alkoxy” embraces an alkyl group attached to an 
oxygen. Examples include, without limitation, methoxy, 
ethoxy, tert-butoxy, and cyclohexyloxy. Most preferred are 
“lower alkoxy' groups having one to six carbon atoms. 
Examples of Such groups include methoxy, ethoxy, propoxy, 
butoxy, isopropoxy, and tert-butoxy groups. 
The term “alkenyl embraces unsaturated aliphatic groups 
analogous in length and possible Substitution to the alkyls 
described above, but that contain at least one double bond. 
Examples include propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 
2-methylpropenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 
4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-me 
thyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 
3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-bute 
nyl, 3-methyl-3-butenyl, and the like. 
The term “alkenoxy” embraces an alkenyl group attached 
to an oxygen. Examples include allyloxy, 1-propenyloxy, 
isopropenyloxy, methallyloxy, 2-butenyloxy, 1-butenyloxy, 
isobutyloxy, pentenyloxy, hexenyloxy, octenyloxy, or dece 
nyloxy. 
The term “alkenoxyalkyl embraces an alkenoxy-substi 
tuted alkyl moiety. Examples include allyloxymethyl, ally 
loxyethyl, allyloxypropyl, and methallyoxymethyl. 
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The term “aryl” embraces a carbocyclic aromatic system 
containing one, two, or three rings wherein Such rings may be 
attached together in a pendant manner or may be fused. The 
term “fused’ means that a second ring is present (i.e., attached 
or formed) by having two adjacent atoms in common (i.e., 
shared) with the first ring. The term “fused' is equivalent to 
the term “condensed.” The term “aryl” embraces aromatic 
groups such as phenyl, naphthyl, tetrahydronaphthyl, indane, 
and biphenyl. 
The term “arylalkyl or “aralkyl embrace aryl-substituted 
alkyl moieties. Preferable aralkyl groups are “lower aralkyl 
groups having aryl groups attached to alkyl groups having 
one to six carbon atoms. Examples of Such groups include 
benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and 
diphenylethyl. The terms benzyl and phenylmethyl are inter 
changeable. 
The term “aryloxy” embraces aryl groups, as defined 
above, attached to an oxygen atom, such as phenoxy. 
The term “aralkoxy' or “arylalkoxy” embrace aralkyl 
groups attached through an oxygen atom to other groups. 
“Lower aralkoxy' groups are those phenyl groups attached to 
lower alkoxy group as described herein. Examples of Such 
groups include benzyloxy, 1-phenylethoxy, 3-trifluo 
romethoxybenzyloxy, 4-propylbenzyloxy, and 2-phe 
nylethoxy. 
The term silyl refers to the group —SiHi. The silyl group 
may be optionally Substituted with one or more alkyl, aryl, 
arylalkyl, alkoxy, aryloxy, arylalkoxy groups, or combina 
tions thereof. Thus, for example, the term “alkylsilyl 
embraces a silyl group Substituted with one or more alkyl 
groups, such as methylsilyl dimethylsilyl, trimethylsilyl eth 
ylsilyl, diethysilyl, triethylsilyl, and the like. The term “aryl 
silyl similarly refers to a silyl group substituted with one or 
more aryl groups, such as phenylsilyl. The term “arylalkylsi 
lyl refers to a silyl group substituted with one or more ary 
lalkyl groups. The term alkoxysilyl refers to a silyl group 
substituted with one or more alkoxy groups. The term “ary 
loxysilyl embraces silyl groups substituted with one or more 
aryloxy groups. The term “arylalkoxysilyl embraces silyl 
groups substituted with one or more arylalkoxy groups. 
The term “siloxy' embraces oxy-containing groups Substi 
tuted with a silyl group. The siloxy group may be optionally 
Substituted with one or more alkyl, aryl, arylalkyl, alkoxy, 
aryloxy, arylalkoxy groups, or combinations thereof. Thus, 
for example, the term “alkylsiloxy' embraces a siloxy group 
substituted with one or more alkyl groups. The term “arylsi 
loxy” embraces a siloxy group Substituted with one or more 
aryl groups. The term “arylalkylsiloxy” embraces a siloxy 
group Substituted with one or more arylalkyl groups. The 
term “alkoxysiloxy” embraces a siloxy group substituted 
with one or more alkoxy groups. The term “aryloxysiloxy” 
embraces a siloxy group Substituted with one or more aryloxy 
groups. The term “arylalkoxysiloxy” embraces a siloxy group 
Substituted with one or more arylalkoxy groups. 
The term “silylalkyl embraces silyl-substituted alkyl moi 
eties. The silylalkyl groups may be optionally substituted 
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary 
lalkoxy groups, or combinations thereof. Thus, for example, 
the term “alkylsilylalkyl embraces methylsilylpropyl, dim 
ethylsilylpropyl, thmethylsilylpropyl, and the like. The term 
“arylsilylalkyl embraces aryl-substituted silylalkyl groups. 
The term “arylalkylsilylalkyl embraces arylalkyl substituted 
silylalkyl groups. The term “alkoxysilylalkyl embraces 
alkoxy substituted silylalkyl groups. The term “aryloxysily 
lalkyl embraces aryloxy substituted silylalkyl groups. The 














The term “siloxyalkyl embraces siloxy-substituted alkyl 
groups. The siloxyalkyl groups may be optionally Substituted 
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary 
lalkoxy groups, or combinations thereof. Thus, the term 
“alkylsiloxyalkyl embraces alkyl substituted siloxyalkyl 
groups. The term “arylsiloxyalkyl embraces aryl substituted 
siloxyalkyl groups. The term “arylalkylsiloxyalkyl 
embraces arylalkyl Substituted siloxyalkyl groups. The term 
“alkoxysiloxyalkyl embraces alkoxy substituted siloxyalkyl 
groups. The term “aryloxysiloxyalkyl embraces aryloxy 
substituted siloxyalkyl groups. The term “arylalkoxysiloxy 
alkyl embraces arylalkoxy Substituted siloxyalkyl groups. 
The term “silylalkoxy” embraces silyl-substituted alkoxy 
groups. The silylalkoxy group may be optionally Substituted 
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary 
lalkoxy groups, or combinations thereof. Thus, for example, 
the term “alkylsilylalkoxy” embraces alkyl substituted sily 
lalkoxy groups. The term “arylsilylalkoxy” embraces aryl 
substituted silylalkoxy groups. The term “arylalkylsilyla 
lkoxy' embraces arylalkyl Substituted silylalkoxy groups. 
The term “alkoxysilylalkoxy” embraces alkoxy substituted 
silylalkoxy groups. The term “aryloxysilylalkoxy” embraces 
aryloxy substituted silylalkoxy groups. The term “arylalky 
loxysilylalkoxy” embraces arylalkyloxy substituted silyla 
lkoxy groups. 
The term “siloxyalkoxy” embraces siloxy-substituted 
alkoxy groups. The siloxyalkoxy group may be optionally 
Substituted with one or more alkyl, aryl, arylalkyl, alkoxy, 
aryloxy, arylalkoxy groups, or combinations thereof. Thus, 
for example, the term “alkylsiloxyalkoxy” embraces alkyl 
substituted siloxyalkoxy groups. The term “arylsiloxy 
alkoxy” embraces aryl substituted siloxyalkoxy groups. The 
term “arylalkylsiloxyalkoxy” embraces arylalkyl substituted 
siloxyalkoxy groups. The term “alkoxysiloxyalkoxy.' 
embraces alkoxy Substituted siloxyalkoxy groups. The term 
“aryloxysiloxyalkoxy” embraces aryloxy substituted siloxy 
alkoxy groups. The term “arylalkoxysiloxyalkoxy' embraces 
arylalkyloxy Substituted siloxyalkoxy groups. 
The biomaterial composition of the present invention com 
prises an organosilicon monomer (such as a silorane) and a 
chemical curing system or dual chemical/light curing system 
for polymerizing the monomer. The compositions may also 
contain TOSUs and/or fillers. The compositions may also 
include one or more accelerators, such as photoacids. Photo 
sensitizers, and/or reaction promoters may also included in 
the biomaterial composition having the dual chemical/light 
curing systems. In addition, one or more pre-polymerized 
organosilicon monomers may also be included in the bioma 
terial composition. The pre-polymerized organosilicon 
monomers essentially function as a filler in the overall bio 
material composition. 
In an exemplary aspect, the biomaterial composition com 
prises about 30 to 60 wt % (e.g., about 30, 35, 40, 45, 50, 55, 
or 60 wt % most preferably about 40 to 55 wt %) organo 
silicon monomer (e.g., silorane co-monomer, Such as Sil 
Mix); about 0 to 50 wt % (e.g., about 1, 2, 3, 4, 5, 10, 15, 20, 
25, 30,35, 40, 45, or 50 wt % most preferably about 25 to 50 
wt %) pre-polymerized organosilicon monomer (e.g., pre 
polymerized silorane filler, such as SilMix); about 0 to 25 wt 
% (e.g., about 5, 10, 15, 20, or 25 wt % most preferably 
about 10 to 20 wt %) other filler (e.g., glass, such as an 
unmodified glass filler); and about 0.05 to 5 wt % (e.g., about 
0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 
0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 
2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %) 
of the chemical cure or dual chemical/light curing system. For 
example, the chemical cure system may comprise about 0.05 
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to 1.0 wt % (most preferably about 0.05 to 0.2 wt %) p-(oc 
tyloxyphenyl)phenyliodonium hexafluoroantimonate and 
about 0.05 to 1.0 wt % (most preferably about 0.09 to 0.2 wt 
%) Lamoreaux's catalyst. 
As another example, the biomaterial composition com 
prises about 30 to 60 wt % (e.g., about 30, 35, 40, 45, 50, 55, 
or 60 wt % most preferably about 35 to 50 wt %) organo 
silicon monomer (e.g., silorane co-monomer, Such as SilMix) 
and about 0 to 80 wt % (e.g., about 5, 10, 15, 20, 25, 30, 35, 
40, 45, 50, 55, 60, 65, 70, 75, or 80 wt % most preferably 
about 45 to 65 wt %) filler (e.g., DY5 filler modified with 
ECHE, 3TOSU, or 1TOSU); and about 0.05 to 5 wt % (e.g., 
about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3, 0.4,0.5,0.6, 
0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 
2.4, 2.6.2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 
wt %) of the chemical cure or dual chemical/light curing 
system. For example, the dual chemical/light curing system 
may comprise about 0.05 to 1.0 wt % (preferably about 0.3 to 
0.8 wt %) Lamoreaux's catalyst and a photoinitiation system 
comprising about 1 to 5 wt % of an accelerator (e.g., about 3 
wt % PIH), about 0.05 to 2 wt % photosensitizer (e.g., about 
1 wt % camphorquinone), and 0.05 to 0.5 wt % electron donor 
(e.g., about 0.15 wt % EDMAB). 
As another example, the biomaterial composition com 
prises about 20 to 98 wt % (e.g., about 30, 35, 40, 45, 50, 55, 
60, 65, 60, 65,70, 75,80, 85,90,91, 92,93, 94, 95, 96, 97,98 
wt % most preferably about 90 to 98 wt % for the “neat” 
biomaterial composition) organosilicon monomer (e.g., silo 
rane co-monomer, such as SilMix); about 0 to 80 wt % (e.g., 
about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 
or 80 wt % most preferably about 45 to 65 wt %) filler (e.g., 
DY5 filler modified with ECHE, 3TOSU, or 1TOSU); and 
about 0.05 to 5 wt % (e.g., about 0.05, 0.06, 0.07, 0.08, 0.09, 
0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 
1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 
4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %) of the chemical cure or dual 
chemical/light curing system. For example, the dual chemi 
cal/light curing system may comprise a mixture and acid 
(preferably a Bronsted acid), photoacid, and a photosensi 
tizer. The ratio of the Bronsted acid to the photoacid is pref 
erably between about 3:1 to 1:3 by weight (e.g., about 3:1, 
2:1, 1:1, 1:2, and 1:3). The ratio of the Bronstead acid to the 
photosensitizer is preferably about 10:1 to 1:1 by weight (e.g., 
about 10:1, 8:1, 5:1, 3:1, and 1:1). In an exemplary aspect, the 
biomaterial composition may comprise a dual chemical/light 
cure system comprised of acetic acid, PIH, and cam 
phorquinone at a ratio of about 3:3:1 percent by weight, e.g., 
about 3 wt % acetic acid, 3 wt % PIH, and 1 wt % cam 
phorquinone (for a neat biomaterial composition containing 
no filler) and 1.5 wt % acetic acid, 1.5% PIH, and 0.5% 
camphorquinone (for a 50% filled biomaterial composition). 
Each of the components of the composition of the present 
invention will now be described in further detail. 
Organosilicon Monomers 
Various organosilicon monomers useful in the biomaterial 
compositions of the present invention are set forth in Chap 
pelow, U.S. Published Patent Application No. 2007/0072954; 
Weinmann et al., U.S. Pat. No. 6,908,953: Weinmann et al., 
U.S. Pat. No. 6.245,828 entitled “Polymerizable Composi 
tions Based on Epoxides’ and Bissinger et al., U.S. Pat. No. 













Monomers, Production Thereof in Polymerizable Materials;” 
Weinmann et al., Siloranes in dental composites, Dent. Mater. 
21(1) 68-74 (2005); Eicket al., Properties of silorane-based 
dental resins and composites containing a stress-reducing 
monomer, Dent. Mater. 23(8) 1011-1017 (2007); all of which 
are incorporated by reference. Most preferred organosilicon 
monomers are "siloranes, which generally refer to silicon 
containing monomers having an oxirane (epoxide) and pref 
erably a siloxane (e.g., Si-O bond or Si-O-Si-O). 
A variety of organosilicon compounds with oxirane func 
tionality were first synthesized and polymerized by Sato et 
al., JP Patent No. 51033541 (Sep. 20, 1976). Similar com 
pounds were studied by Crivello and others. See Crivello et 
al., European Patent No. 574264 (1993); and Crivello et al., 
European Patent No. 412430 (1991), which are incorporated 
by reference. Most preferred are multifunctional 
cycloaliphatic siloxane-based oxiranes. Exemplary organo 
silicon monomers useful for forming the dental matrix resins 
of the present invention include di-3,4-epoxy cyclohexylm 
ethyl-dimethyl-silane (DiMe-Sil: RY 349660-80-6: 
MF, as Si; 95% purity), 1,4-bis(2,3-epoxypropylox 
ypropyl-dimethylsilyl)benzene (Phen-Glyc: RN 18715-54-3: 
MF, C.H.O.S: 97% purity), and 1,3,5,7-tetrakis(ethy 
cyclohexane epoxy)-1,3,5,7-tetramethyl cyclotetrasiloxane 
(CYGEP: RN 121225-98-7, MF, C.H.O.S., 98% purity), 
all available from 3M-ESPE (St. Paul, Minn.). Exemplary 
siloranes are set forth in Weinmannet al., Volume shrinkage of 
a new filling material based on siloranes, J. Dent. Res. 80(SI) 
780 Abstr. No. 2027 (2001); Weinmann et al., Comparative 
testing of volumetric shrinkage and sealing of silorane and 
methacrylate filling materials, J. Dent. Res. 81 (SI-A) 417 
Abstr. No. 3382 (2002); Dede et al., Comparison of two ways 
to determine polymerization shrinkage of composites, J. 
Dent. Res. 83 (SI-A) Abstr. No. 0057 (2004); Guggenbergeret 
al., Exploring beyond methacrylates, Am J Dent. 1382D-84D 
(November 2000); Schwekl, The induction of gene mutations 
and micronuclei by Oxiranes and siloranes in mammalian 
cells in vitro, J. Dent. Res. 83(1) 17-21 (January 2004); Eick 
et al., Stability of silorane dental monomers in aqueous sys 
tems, J. Dent. 34 (6) 405-410 (2006), Watts, Shrinkage-Stress 
Kinetics of Silorane versus Dimethacrylate Resin-Compos 
ites, 12 Baltimore Convention Center 322-323 (Abstract) 
(March 2005); and Klettke et al., U.S. Pat. No. 6,779.656, 
which are all incorporated by reference. 
Combinations of organosilicon monomers may also be 
utilized in the biomaterial compositions of the present inven 
tion. For example, SilMix is comprised of a 1:1 w/w (2:1 
mol/mol) ratio of methylbis 2-(7-Oxabicyclo[4.1.0 hept-3- 
yl)ethylphenylsilane I (“PHEPSI) and 2,4,6,8-tetramethyl 
2,4,6,8-tetrakis-2-(7-Oxabicyclo4.1.0 hept-3-yl)ethyl-1,3, 
5,7-tetraoxa-2,4,6,8-tetrasilacyclooxtane II (“CYGEP') 
produced by 3M-ESPE (St. Paul, Minn.). The structures Sil 
Mix compounds are shown below: 




The organosilicon monomers used in the biomaterial com 
positions of the present invention are preferably prepared at 
purities greater than 90%, and most preferably greater than 
95% as determined by H NMR spectroscopy. 
The organosilicon monomers preferably comprises about 
20 to 98 wt % (e.g., about 20, 30, 40, 50, 60, 70, or 80%), and 
in some aspects, more preferably about 40 to 60 wt % of the 
composition. Furthermore, as discussed below, the mono 
mers may be pre-polymerized prior to addition to the com 
position so that the biomaterial composition comprises both 
unpolymerized monomers and pre-polymerized polymer 
prior to polymerization. Typically, the ratio of unpolymerized 
monomers (e.g., SilMix co-monomer) to polymer (e.g., pre 
polymerized Sil Mix) is about 1:5 to 5:1 (e.g., about 1:5, 1:4, 
1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1, or some range therebe 
tween). For biomaterial compositions containing pre-poly 
merized organosilicon monomers, the polymer is preferably 
crushed or ground to a particle size (typically irregular in 
shape) of about 0.5 to 15um (e.g., 0.5, 1, 3, 5, 7, 9, 11, 13, or 
15um, or some range therebetween) with a number average 
size of about 2 Lum. The pre-polymerized organosilicon 
monomer essentially functions as a filler in the overall com 
position. 
Cure/Initiation Systems 
The biomaterial compositions of the present invention also 
include a chemical curefinitiation system or a dual chemical/ 
light curing system. 
1. Chemical Cure/Initiation System 
In one aspect, the chemical curing system comprises a 
hydrosilation catalyst which may be used to effect the addi 
tion of the ethylenically unsaturated epoxide or epoxide/or 
ganic mixture. Preferred catalysts are those taught by Lam 
oreaux in U.S. Pat. Nos. 3,917,432: 3, 197433; and 3,220, 
972, which are all hereby incorporated by reference. The 
platinum catalyst disclosed in the patents to Lamoreaux is a 
complex formed from chloroplatinic acid with up to about 2 
moles per gram of platinum of a member selected from the 
class consisting of alcohols, ethers, aldehydes, and mixtures 
of the above. This catalyst will sometimes be referred to 
herein as the “Lamoreaux catalyst.” 
In a preferred aspect, the chemical curing system com 
prises a Lamoreaux's catalyst which involves either PtCl 
with aldehyde and ether linkages derived from octanol. This 
catalyst was synthesized from chloroplatinic acid HPtCle. 
using an adapted procedure by Lamoreaux, U.S. Pat. No. 













1N1\-1N1 So -3- 50° C. PtCl2 Complex 
In one aspect, Lamoreaux's catalyst may be prepared by 
heating the reaction mixture to 70° C. at 25 mm Hg for 40 
hours as discussed in the patent references. In another aspect, 
Lamoreaux's catalyst may be prepared by heating the reac 
tion mixture (chloroplatinic acid hexahydrate and octanol 
(98%) combined in a 1:7 mole ratio) to 50 to 55° C. under 
vacuum at 0.01 mm Hg for about 40 to 42 hours. After that 
time, the solution was filtered and washed with hexanes. The 
filtrate was placed under vacuum (0.01 mm Hg) at room 
temperature for about 8 to 12 hours. The resulting liquid was 
stored under inert atmosphere in the refrigerator. 
Further, other organometallic catalysts, such as those con 
taining ruthenium, rhodium, iridium, palladium, platinum, 
iron, osmium, cobalt, molybdenum, tungsten, nickel, copper, 
gold, silver, Zirconium, and titanium (most preferably Pt and/ 
or Rh) are also possibilities for chemical curing. For example, 
for platinum-based catalysts, Wilkinson's catalyst, Speier's 
catalyst, and Karstedt's catalyst may also be employed, while 
Grubb’s catalyst may be a suitable ruthenium-based catalyst. 
The chemical curing system may optionally contain an 
accelerator. A preferable accelerator is a photoacid, such as 
those described in Akizumi et al., U.S. Published Patent 
Application No. 2011/0172323, which is incorporated herein 
by reference. Most preferred accelerators are aryl-based 
iodonium salts, in particular a phenyl iodonium salt. 
Examples of Such accelerators include, but are not limited to, 
(4-n-octyloxyphenyl)phenyliodonium hexafluoroantimonate 
(“PIH'), which may be obtained from GE Silicones under 
number 479-2092C: 4-(2-hydroxytetradecyloxyphenyl) 
phenyliodonium hexafluoroantimonate (CD 1012), which 
may be obtained from Sartomer under the trade name SarCat 
CD-1012 or from Gelest under the trade name OMANO72: 
4-1-methylethyl)phenyl(4-methylphenyl)iodonium tetrak 
is(pentafluorophenyl)borate(1-) (RHO2074), which may be 
obtained from Rhodia, Inc., under the trade name Rhodorsil 
Photoinitiator 2074; and combinations thereof. See also, 
similar compounds discussed in Yamtao et al., WO 2002/ 
046507, which is incorporated by reference. Although such 
accelerators have been traditionally used in light initiated 
polymerization systems, they also may be used in the chemi 
cal-initiated polymerization composition of the present 
invention. The mechanism by which the photoacid (e.g., PIH) 
reacts with the organometallic catalyst (e.g., Lamoreaux's 
catalyst) to permit polymerization in the dark when using this 
exemplary chemical curing system of the present invention is 
not known. 
It will be appreciated that chemical curing system does not 
require a photosensitizer or reaction promoter (although Such 
compounds could optionally be included in the composition). 
The chemical curing system preferably comprises about 
0.05 to 2 wt % (e.g., 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3, 
0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 
1.8, 1.9, or 2.0 wt %) of the biomaterial composition. For 
example, the chemical cure system may comprise about 0.1 to 
1.0 wt % of the photoacid (e.g., about 0.05 to 0.4 wt %, 
preferably about 0.05 to 0.2 wt %, of p-(octyloxyphenyl) 
phenyliodonium hexafluoroantimonate) and about 0.05 to 1.0 
wt % organometallic catalyst (e.g., about 0.1 to 0.4 wt %, 
preferably about 0.09 to 0.2 wt % Lamoreaux's catalyst). 
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2. Dual Chemical/Light Cure/Initiation System 
In another aspect, the biomaterial compositions of the 
present invention comprise a dual chemical/light cure system. 
One exemplary dual chemical/light cure system comprises a 
mixture of a chemical curing agent (Such as an acid or one of 5 
the organometallic catalysts referenced herein), along with an 
accelerator (see examples above), photosensitizer, and/or 
reaction promoter. 
Chemical Curing Agent (e.g. Acetic Acid Containing Sys 
tems) 
The dual chemical/light cure system may include an acid. 
In the present invention, Various Lewis aids, Bronsted acids, 
and Super acids were investigated. The acids investigated 
included hydrochloric acid, acetic acid (AA'), phosphoric 
acid, Sulfuric acid, hydrobromic acid, hydroiodic acid, 
trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic 
acid, borontrifluoride, aluminium chloride, tin (IV) chloride, 
titanium chloride, pentafluoroproprionic acid, triflic acid, 
hexafluorophosphoric acid (“HFPA), ethyl triflate, potas 
sium t-butoxide, and mixtures thereof (e.g., AA/HFPA, phos 
phoric acid/TiCl, phosphoric acid/triflic acid, phosphoric 
acid/p-toluene Sulfonic acid, and phosphoric acid/trifluoro 
acetic acid). 
The preferred acid investigated is acetic acid. Thus, in one 
aspect, the preferred acid is a weak/mild monoprotic acid 
which is nontoxic and biocompatible. The acid preferably has 
a pKa between about 3 and 6 (e.g., 3, 4, 5, or 6), exhibits low 
Volatility, and is soluble in the organic monomers being poly 
merized. 
Photosensitizer 
The dual curing system also preferably includes one or 
more photosensitizers. Exemplary photosensitizers are dis 
closed in Chappelow et al., U.S. Pat. No. 6,653,486, which is 
incorporated by reference. Suitable sensitizers include com 
pounds in the following categories: ketones, coumarin dyes 
(e.g., ketocoumarins), Xanthene dyes, acridine dyes, thiazole 
dyes, thiazine dyes, oxazine dyes, azine dyes, aminoketone 
dyes, porphyrins, aromatic polycyclic hydrocarbons, p-sub 
stituted aminostyryl ketone compounds, aminotriaryl meth 
anes, merocyanines, squarylium dyes and pyridinium dyes. 
Ketones (e.g., monoketones or alpha-diketones), ketocou 
marins, aminoarylketones, and p-substituted aminostyryl 
ketone compounds are preferred sensitizers. For example, 
Such photosensitizers include, but are not limited to as 2.2-, 
4.4- or 2,4-dihydroxybenzophenone, di-2-pyridyl ketone, 
di-2-furanyl ketone, di-2-thiophenyl ketone, benzoin, fluo 
renone, chalcone, Michler's ketone, 2-fluoro-9-fluorenone, 
2-chlorothioxanthone, acetophenone, benzophenone, 1- or 
2-acetonaphthone, 9-acetylanthracene, 2-, 3- or 
9-acetylphenanthrene, 4-acetylbiphenyl, propiophenone, 
n-butyrophenone, Valerophenone, 2-, 3- or 4-acetylpyridine, 
3-acetylcoumarin and the like. Suitable diketones include 
aralkyldiketones such as anthraquinone, phenanthrene 
quinone, o-, m-, and p-diacetylbenzene, 1.3-, 1.4-, 1.5-, 1.6-, 
17- and 1,8-diacetylnaphthalene, 1.5-, 1.8- and 9,10-diacety 
lanthracene, and the like. Suitable alpha-diketones include 
2,3-butanedione, 2.3-pentanedione, 2.3-hexanedione, 3,4- 
hexanedione, 2.3-heptanedione, 3,4-heptanedione, 2.3-oc 
tanedione, 4.5-octanedione, benzyl, 2,2'-3,3'- and 4,4'-dihy 
droxylbenzyl, furyl, di-3,3'-indolylethanedione, 2.3- 
bomanedione (camphorquinone), biacetyl, 1.2- 
cyclohexanedione, 1.2-naphthaquinone, acenaphthaquinone, 
and the like. 
A preferred photosensitizer is an alpha-dicarbonyl com 
pound. Examples of specific photosensitizers that may be 
used in the composition of the present invention include, but 













obtained from Aldrich under the number 12, 489-2 with a 
97% purity: 2-chlorothioxanthen-9-one (“CTXO), which 
may be obtained from Aldrich C7-240-4; and combinations 
thereof. 
Reaction Promoter (Electron Donor) 
Another preferred component of the dual chemical/light 
curing system is one or more electron donor compounds, 
which functions as a reaction promoter. A class of donor 
compounds that may be useful in the inventive systems may 
be selected from some of the electron donors described in 
Chappelow et al., U.S. Pat. No. 6,653,486 and Palazzotto et 
al., U.S. Pat. No. 5,545,676, which are both incorporated by 
reference. Preferred electron donor compounds include sub 
stituted amines, e.g., ethyl dimethylaminobenzoate. The pre 
ferred electron donor that may be used in the composition of 
the present invention include, but are not limited to, ethyl 
p-dimethylaminobenzoate (“EDMAB), which may be 
obtained from Acros under number 11840-1000 at 99.9% 
purity; 4,4'-bis(diethylamino)benzophenone (“BDEAB), 
which also may be obtained from Acros under number 17081 
0250s at 99% purity; and combinations thereof. 
The dual chemical/light curing system preferably com 
prises about 0.05 to 5 wt % (e.g., 0.05, 0.06, 0.07, 0.08, 0.9, 
0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 
1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 
3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %) of the biomedical 
composition. 
Exemplary Dual Chemical/Light Curing Systems 
In exemplary embodiments, the dual chemical/light curing 
system may comprise 0.05 to 0.2 wt % (preferably about 0.3 
to 0.8 wt %) Lamoreaux's catalyst and a photoinitiation sys 
tem comprising about 1 to 5 wt % of an accelerator (e.g., 
about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 wt %, preferably about 
3 wt % PIH), about 0.05 to 2 wt % photosensitizer (e.g., about 
0.05, 1, 1.5, 2 wt %, preferably about 1 wt % cam 
phorquinone), and 0.05 to 0.5 wt % electron donor (e.g., 0.05, 
0.1, 0.15, 0.2,0.25, 0.3, 0.35, 0.4,0.45, 0.5 wt %, preferably 
about 0.15 wt % EDMAB). 
In another exemplary aspect, the dual chemical cure sys 
tem comprises an acid (e.g., acetic acid), a photosensitizer 
(e.g., camphorquione), and a photoacid (e.g., PIH). The ratio 
of the Bronsted acid to the photoacid is preferably between 
about 3:1 to 1:3 by weight (e.g., about 3:1, 2:1, 1:1, 1:2, and 
1:3). The ratio of the Bronstead acid to the photosensitizer is 
preferably about 10:1 to 1:1 by weight (e.g., about 10:1, 8:1, 
5:1, 3:1, and 1:1). For example, the composition may com 
prise a dual chemical/light cure system comprised of acetic 
acid, PIH and camphorquinone at a ratio of about 3:3:1 per 
cent by weight. For example, the composition may comprise 
about 1.5 wt % acetic acid, 1.5% PIH, and 0.5% cam 
phorquinone (for a 50% filled composition). The percentage 
by weight is preferably 3:3:1 of AAPIH:CQ. 
Fillers 
The biomaterial compositions may further comprise one or 
more fillers. These fillers can possess a variety of morpholo 
gies such as, but not limited to, needles, rods, particulate, 
flakes, plates, cylinders, long fibers, whiskers, or spherical 
particles. In some embodiments that may be preferred, the 
filler is comprised of particles with an average particle size 
which is in the Sub-micron or nanoparticle range, e.g., less 
than about 1.0 um. Exemplary particle sizes are about 10, 20, 
30, 40, 50, 60, 70, 80,90, 100, 150, 200, 250, 300, 350, 400, 
450, 500, 600, 700, 900, or 1000 nm or some range therebe 
tWeen. 
Given the appropriate interactions and dispersion qualities, 
particle size may be a critical factor in that nanoparticles can 
produce dramatic changes in the mechanical properties of the 
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composition as compared to micrometer sized fillers at com 
parable Volume loading to analogous nanoparticle compos 
ites. For example, improvements in tensile strength and 
modulus offive- and seven-fold may be obtained for compos 
ites containing only 1.5% nanoclay particles. Similar low 
loadings with resulting increased properties have been 
reported elsewhere. Surprisingly, higher concentrations of 
nanoparticles made little further improvement. Improved 
strength and wear properties at low filler Volume loading are 
anticipated if the particles are not subject to being ablated 
from the matrix, i.e., are prevented from discreet particle 
ablation by covalent bonding of the particles into the polymer 
matrix. 
The filler may be comprised of an inorganic or organic 
material, which may be bioactive. In certain embodiments, 
the filler is comprised of an inorganic material. 
Suitable fillers may be particulate or fibrous fillers with 
sizes in the nanoparticle to microparticle range. Fillers should 
be capable of being covalently bonded to the resin matrix 
itself or to a coupling agent that provides bonding to the filler 
and then the Surrounding resin matrix. Examples of Suitable 
filling materials include but are not limited to amorphous 
silica; spherical silica; colloidal silica, clays; barium glasses; 




Composition of the macro and micro fillers will not be iden 
tical or perhaps even similar. Nanoparticles will be typically 
high purity, high strength whiskers/rod/fibers/platelets, while 
the macrofiller will typically be a silica-based ally glass with 
additive elements for strength and hardness. 
In another aspect, examples of suitable fillers include, but 
are not limited to, barium glass, barium-boroaluminosilicate 
glass, sodium borosilicate, silica, 45S5 glass, bioactive glass, 
ceramics, glass-ceramics, bioactive synthetic combeite glass 
ceramic, e-glass, S-glass, iron phosphate, or combinations 
thereof. The most preferred fillers are yttria alumino silicate 
(e.g., DY5; see table below) and barium boroaluminosilicate 
(e.g., M12, see table below), and alumina or Zirconia nano 
rods. 
Preferred glass fillers can be made by either melting 
batches (M-series and alkali-containing DY-series) or by sin 
tering batches and spheroidization of the sinter (alkali-free 
DY-series). The sinter/spheroidization process was used for 
batches that melted above 1550° C. The nominal chemical 
composition and n of the M-series glasses are given in Table 
1 below. The nominal chemical composition and n of the 
DY-series glasses are listed in Table 2 below. The n of the 
glasses varied from 1.48 to 1.56 depending on composition, a 
range of values which is needed for reinforcing blue-light 
(440 nm)-curable composites. 
TABLE 1. 
Nominal Weight Percent Composition and Refractive Index of M-Series 
Filler Code Li2O Na2O K2O MgO BaO CaO YO. ZrO2 YbO, ZnO TiO2 B2O. Al2O. SiO2 AIF in 
M1 3 O O 2 9 O 3 O O O O S8 14 8 3 1.53 
M2 3 O O 2 9 O 3 O O O O 29 14 37 3 152 
M3 3 O O 2 9 O O O 3 O O 29 14 37 3 152 
M4 3 O O 2 9 O 3 O O O O S8 O 22 3 1.53 
M5 O 1 O 8 O O O 9 O O O O 21 61 0 1.52 
M6 O 1 O 2 O 22 O 5 O O O 7 11 S2 O 1.56 
M7 O 10 O 1 O 6 O 22 O O O 3 4 S4 O 1.56 
M8 O 6 8 O 2 6 O 5 O 5 O O 2 66 O 1.52 
M9 O 5 6 O O O O 5 O 7 4 8 4 61 0 1.52 
M10 3 O O 2 9 O 3 O O O O S8 14 8 3 1.52 
40 
carbonate; fluoroaluminosilicate; barium sulfate; quartz; TABLE 2 
barium silicate; strontium silicate; barium borosilicate; 
barium boroaluminosilicate; strontium borosilicate; stron- Nominal Weight Percent Composition and 
- Refractive Index of DY-Series Glasses tium boroaluminosilicate; bioactive glass; dental glass iono 
mer filler; silicate or phosphate based glass fibers; lithium * Filler Code Y2O, Yb2O3. Al2O3 SiO2 Na2O in 
silicate; ammoniated calcium phosphate; deammoniated cal- DYb1 O 23 21 56 O 155 
cium phosphate; calcium tungstate; alumina; Zirconia; tin DY2 1 O 9 90 O 148 
oxide; Zinc oxide; calcium oxide; magnesium oxide, postas- DY3 3 O 9 88 O 148 
sium oxide, barium oxide yttrium oxide, bismuth compounds DY4 15 O 21 64 O 1.56 50 DY5* 15 O 5 8O O 1.52 
Such as bismuth oxychloride and bismuth oxide; polymer DY6 15 O 15 70 O 1.53 
powders such as polymethyl methacrylate, polystyrene, and DY7 14 O 14 67 5 1.52 
polyvinyl chloride; titanium dioxide; bound and nano struc- R t g t 5. I 
tured silica fillers as set forth in U.S. Pat. No. 6,417,246, DY1O O 23 21 56 O 152 
which is hereby incorporated by reference; densified and 55 
cký -- 2 
embrittled glass fibers or particles as set forth in U.S. Pat. Vickers microhardness 6.2 GPa (739 + 22 kg/mm.) 
Nos. 6,013,694 and 6,403,676 which are hereby incorporated Nanoparticles assist cement formulation, reinforcing and 
by reference; fibrous material and one or more forms of strengthening the interstitial domains within the composition, 
surface-modifying particles bonded thereto as set forth in obtaining radiopacity when not obtained via the macrofiller, 
U.S. Pat. No. 6,270,562 which is hereby incorporated by 60 and hardening the surface against wearby increasing the filler 
reference; polyhedral oligomeric silsesquioxane fillers as set Volume concentration. While spherical or irregular nanopar 
forth in U.S. Pat. No. 6,653,365 which is hereby incorporated ticles are used in current formulations, whisker/nanorods 
by reference; nanostructures such as POSSTM (polyhedral and/or clay platelets may also be used for interstitial strength 
oligomeric silsesquioxane) Supplied by Hybrid Plastics; and ening of the macroparticle filled composite where obtained at 
combinations of all the fillers mentioned. Preferred fillers 65 low filler volume loading. An increased aspect ratio is impor 
include titanium oxide and/or calcium phosphate since these 
materials help promote mineralization and bone adhesion. 
tant to mechanical strength, minimization of crack initiation, 
and can Support mineralization by osteoblast cells though 
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spherical or irregular nanoparticles that can also be utilized to 
reinforce the interstitial composite so long as a suitable Sur 
face modification or coupling agent is utilized to strengthen 
bone across the polymer-particle interface. Clay/nanowhis 
ker/nonrod dimensions are preferred that have aspect ratios 
greater than 10:1 up to about 100:1. Clays include montmo 
rillonites and nanowhisker/nanorod includes boehmite, alu 
mina, Zirconia, yttria-Stabilized Zirconia, titania, calcium 
phosphate, or hydroxyl apatite. 
Surface modifications can be used to control interparticle 
association, dispersion viscosity, and reactivity with the Sur 
rounding matrix. In one aspect, nanospheres or nanofillers, 
typically up to 500 nm in length and 30 nm in diameter may 
be used. Normal, glass filled systems can also be used for 
dispersion quality, flexural strength, hardness, internal poly 
merization stress, efficiency of cure, and cell toxicity of the 
resulting composite. Compositions of the nanofibers include 
alumina nanospheres and nanorods, which have produced 
improved tensile and flexural strength. While alumina has 
provided remarkable property improvements, Zirconium-yt 
trium oxide fiber synthesis, whose fibers have better pH sta 
bility compared to alumina, may also be used. Nanorods will 
be synthesized via gel formation followed by chemically 
templating in conventional oven or by autoclave, as appropri 
ate for the desired geometry. 
Montmorillonite clays are the most common member of 
the Smectite clay family having plate-like primary particles 
that possess an anionic Surface with ionically bound cations to 
maintain Surface charge neutrality. Natural montmorillonite 
clay has sodium counterions on the Surface; however, these 
Sodium atoms can be ion-exchanged with other inorganic or 
organic ions to change the surface chemistry of the clay 
particles. In addition, natural montmorillonite clay particles 
are stacked upon one another due to the charge-charge inter 
action between the clay platelets. Once the counterion is 
exchanged for an organic ion or group, the replacement facili 
tates the separation of the clay lattice, especially when pen 
etrated by Solvents, monomer or polymer chains, called inter 
calation. The particles may then be further dispersed into 
discreet nanoplatelets resulting in what is called an exfoliated 
clay material. Upon synthesis of exfoliated structures, large 
mechanical property improvements of a composite compared 
to neat polymer properties are obtained at rather low clay 
filler concentration levels. 
Such fillers include, but are not limited to, a hydroxyapatite 
in the form of hollow microspheres or biocompatible, biode 
gradable glass. The microspheres of hydroxyapatite could be 
used to contain and act as carriers for antibiotics. Other com 
ponents of the composites that could be delivered within the 
hydroxyapatite microspheres include growth factors such as 
bone morphogenetic proteins (“BMPs), cartilage-derived 
morphogenic proteins (“CDMPs'), collagen, or small mol 
ecules that are being developed to promote bone growth 
through blood vessel formation. In one aspect, the growth 
factor is selected from the group consisting of TGFB1, 
TGFB2, TGFB3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, 
BMP-7, BMP-8, BMP-9, CDMP-1, CDMP-2, or CDMP-3. 
For silorane composites, good interfacial properties 
between polymer resin and fillers improve composite prop 
erties and performance. There are variables of group density 
and structure, which affect Surface wetting, reactivity, inter 
facial structure, and composite strength. The inclusion of a 
Surface coupling agent or ligand increases the critical con 
centration of particle fillers that can be added by enhancing 
Surface wetting and dispersion viscosity. Interfacial proper 
ties are even more critical since the intended application 













ronment. Interfaces between filler and resin matrix are prime 
locations for weakening through ingress of moisture. How 
ever, interfaces can be strengthened through surface modifi 
cation of fillers resulting in greater mechanical properties to 
enable not only interaction, but also reaction with the sur 
rounding polymer matrix, including chain extension, 
between filler and polymer matrix. Several types of surface 
modifications may be used to improve strength through 
development of covalent interface architectures during cure. 
Surface modifications are produced through exposure to 
dilute solutions to prevent multi-layer, weak, adsorbed struc 
tures and provide better ligand access to filler surfaces. After 
washing particles thoroughly of excess reagent, groups are 
quantified by thermogravimetric analysis (TGA) for com 
parison to bare particles. Fourier transform infrared spectros 
copy (FTIR), X-ray photoelectron spectroscopy (XPS), and 
Surface density calculated from weight loss using known 
particle Surface area and correcting for bulk and adsorbed 
water loss is used to analyze the filler Surface coating. Surface 
tension and wetting of filler powders is readily measured 
using tensiometry through the Washburn equation. 
The filler typically is about 0, 5, 10, 15, 20, 25, 30, 40, 45, 
50, 55, 60, or 70 wt % (or some range therebetween) of the 
biomaterial composition. 
TOSUs and TOSU-Like Compounds 
TOSUs may optionally be added to the biomaterial com 
positions of the present invention. The TOSUs may be clas 
sified as 1,5,7,1'-tetraoxaspiro5.5undecanes or 2.4,8,10-tet 
raoxaspiro5.5undecanes. The TOSUs may or may not have 
a silicon-containing moiety. The TOSUs are preferably a 
potential expanding monomer type. By using the TOSUs, the 
composition has the potential of reducing the amount of poly 
merization stress of the total formulation. 
Various TOSUs are set forth in Chappelow, U.S. Published 
Patent Application No. 2007/0072954; Chappelow et al., U.S. 
Pat. No. 6,825.364; Chappelow et al., U.S. Pat. No. 6,653, 
486; Chappelow et al., U.S. Pat. No. 6,658,865; Byerley et al., 
U.S. Pat. No. 5,556,896; Guest, U.S. Pat. No. 3,023,2221; 
Sadhir & Luck, Expanding Monomers. Synthesis, Character 
ization, and Applications, CRC Press, Boca Raton, Fla. 
(1992); Rokicki, Aliphatic cyclic carbonates and spiroortho 
carbonates as monomers, Prog. Polym. Sci. 25 259-342 
(2000): Imai et al., JP 28196665B2; and Porret et al., JP 
03099086; which are all incorporated by reference. An 
important synthetic precursor is 3,9-diethyl-3.9-bis(ally 
loxymethyl)-1.5.7.11-tetraoxaspirol5.5undecane (DE 
BAOM-1.5.7.11-TOSU), and is a six-member ring spiroor 
thocarbonate that is a liquid at room temperature. The vinyl 
groups on this molecule permit the addition of a wide variety 
of reactive and unreactive functionalities by electrophilic and 
radical means. These functionalities can be both symmetric 
and asymmetric. 
In one aspect of the present invention, TOSUs according to 
Formulas A1 or A2 may be utilized in the biomaterial com 
positions: 
(A1) 
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-continued 
R1 O O R3 
six X). O O 
wherein RandR are independently is alkyl, aryl, aralkyl, 
or hydrogen; and 
wherein R and Rare independently alkenoxy, alkenoxy 
alkyl, or silicon-containing moiety selected from alkylsilyl, 
arylsilyl, arylalkylsilyl, alloxysilyl, aryloxysilyl, arylalkox 
ysilyl alkylsiloxy, arylsiloxy, arylalkylsiloxy, alkoxysiloxy, 
aryloxysiloxy, arylalkoxysiloxy, alkylsilylalkyl, arylsilyla 
lkyl, arylalkysilylalkyl, alkoxysilylalkyl, aryloxysilylalkyl, 
arylalkoxysilylalkyl, alkylsiloxyalkyl, arylsiloxyalkyl, aryla 
lkylsiloxyalkyl, alkoxysiloxyalkyl, aryloxysiloxyalkyl, ary 
lalkoxysiloxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, aryla 
lkylsilylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxy, 
arylalkyloxysilylalkoxy, alkylsiloxyalkoxy, arylsiloxy 
alkoxy, arylalkylsiloxyalkoxy, alkoxysiloxyalkoxy, arylox 
ysiloxyalkoxy, and arylalkoxysiloxyalkoxy. 
In another aspect, the TOSUs are characterized by Formu 
las A1 or A2 wherein R and Ra are independently alkylsily 
lalkyl or alkylsiloxyalkyl. In one preferred aspect, RandR 
are independently trimethylsilylpropyl, trimethylsilylethyl, 
triethylsilyipropyl, or triethylsilylethyl. 
In still another aspect, the TOSU compounds according to 
Formula A1 or A2 are characterized such that R and R are 
independently is alkyl, aryl, aralkyl, or hydrogen; and 
wherein R and Ra are independently alkenoxyalkyl or alkyl 
silylalkyl. In still another aspect, RandR are independently 
alkenyloxyalkyl selected from —(CH), O-(CH) - 
CH=CH, and wherein mand n are independently 0, 1, 2, 3, 
4; or alkylsilylalkyl selected from trimethylsilylpropyl and 
trimethylsilylethyl. 
In another aspect, the TOSU compounds according to the 
Formula A2 are characterized such that R and R are inde 
pendently alkyl, aryl, aralkyl, or hydrogen; and wherein R 
and Ra are independently alkenyl, alkenoxy, alkenoxyalkyl, 
or silicon-containing moiety selected from alkylsilyl, arylsi 
lyl, arylalkylsilyl, alloxysilyl, aryloxysilyl, arylalkoxysilyl, 
alkylsiloxy, arylsiloxy, arylalkylsiloxy, alkoxysiloxy, arylox 
ysiloxy, arylalkoxysiloxy, alkylsilylalkyl, arylsilylalkyl, ary 
lalkysilylalkyl, alkoxysilylalkyl, aryloxysilylalkyl, aryla 
lkoxysilylalkyl, alkylsiloxyalkyl, arylsiloxyalkyl, 
arylalkylsiloxyalkyl, alkoxysiloxyalkyl, aryloxysiloxyalkyl, 
arylalkoxysiloxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, ary 
lalkylsilylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxyary 
lalkyloxysilylalkoxy, alkylsiloxyalkoxy, arylsiloxyalkoxy, 
arylalkylsiloxyalkoxy, alkoxysiloxyalkoxy, aryloxysiloxy 
alkoxy, and arylalkoxysiloxyalkoxy. 
In another aspect, the TOSU compounds according to the 
Formula A1 or A2 are characterized such that R and R are 
independently alkyl, aryl, aralkyl, or hydrogen; and wherein 
R and Ra are independently alkenyl, alkenoxyalkyl, and 
alkylsilylalkyl. In still a further aspect, R and R are inde 
pendently alkenyl selected the group consisting of —(CH), 
—CH=CH, and wherein n is independently 0, 1, 2, 3, 4; or 
alkenyloxyalkyl selected from —(CH), O—(CH2)— 
CH=CH, and wherein mand n are independently 0, 1,2,3, 
4; or alkylsilylalkyl selected from trimethylsilylpropyl and 
trimethylsilylethyl. 
In another aspect, R. R. R. and Ra are independently 
selected from the group consisting of alkyl, olefin-terminated 




For example, in one aspect, the TOSUs are selected from 
the group consisting of the following compounds: 
3,9-Diethyl-3.9-bis(allyloxymethyl)-1.5.7.11-tetraoxas 
pirol5.5undecane (DEBAOM-1,5,7,11-TOSU) (Example 1 




Hic=g1 No O 
H O 
-- H 
O O CECH 
15 N1 2 
CH5 
9-Bis(3-trimethylsilylpropyl)-1.5.7.11-tetraoxaspiro5.5 
20 undecane (BTMSP-1,5,7,11-TOSU) (Example 2 of Chap 




cane (BAOM-2,4,8,10-TOSU) (Example 3 of Chappelow, 
U.S. Published Patent Application No. 2007/0072954) 
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-- N1 2 
3,9-Bis(2-trimethylsilylethyl)-2,4,8,10-tetraoxaspiro5.5 
undecane (BTMSE-2,4,8,10-TOSU) (Example 4 of Chap 
pelow, U.S. Published Patent Application No. 2007/0072954) 
O O 
50 H H. H. 




5.2.5.2 hexadecane (DECHE-1,5,7,11-TOSU) (Example 5 
of Chappelow, U.S. Published Patent Application No. 2007/ 
0072954) 
O O 








11-TOSU) (Example 6 of Chappelow, U.S. Published Patent 
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For biomaterial compositions containing fillers, stress-re 
ducing monomers like TOSUs may be used for surface modi 
fication through the attachment of a Surface-reactive ligand 
group, Such as a pendant silyl or phosphate, that is reactive 
with the filler oxide surface. The organic moiety provides 
wetting and dispersion, interfacial (cure) reactivity, and inter 
facial strength properties while adding the potential to reduce 
internal stress in the composite. Since group length has a 
direct effect on interfacial bond and thus composite strength, 
the tether length between the reactive group and the surface 
active ligand is one design aspect may be considered. See 
Wang et al., Dharani L. R. Effect of interfacial mobility on 
flexural strength and fracture toughness of glass/epoxy lami 
nates, Journal of Materials Science 34(19) 4873-4882 
(1999); Schuman et al., Surface modified nanoparticles as 
enhanced fillers for dental polymer-particle composites, J 
Dent Res 89 (2010); Schuman et al., Improved dielectric 
breakdown strength of covalently-bonded polymer-particle 
nanocomposites, Composite Interfaces, 17, 719-731 (2010). 
For example, for 3-(9,9-diethyl, 1.5.7.11-tetraoxa-spiro (5.5) 
undec-3-yl)propyl-trimethoxy-silane ("3TOSU”), a surface 
group density of about 26 A2/group was obtained in reacting 
with glass particles or alumina nanorods, measured through 
CHs H2 H 













TOSUs (or compounds having analogous ring systems like 
the compounds shown below) to the silorane and/or as filler 
particle Surface treatment should improve the mechanical 
properties of the silorane composite. The synthesis of (9.9- 
diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)methyl)tri 
methoxysilane (“1TOSU) and (3-(9,9-diethyl-1,5,7,11-tet 
raoxaspiro5.5undecan-3-yl)propyl)trimethoxysilane 
(“3TOSU) is shown in the schemes below. 
Scheme 1: Synthesis of 1-TOSU 
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Scheme 3: Non-TOSU monomers of similar reactivity and properties 
as TOSU 
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2-trimethoxysilylpropyloxyethyl 
1,4,6-trioxaspiro4.6 undecane 
The TOSUs (or TOSU-like compounds) preferably com 
prises about 0 to 25% by weight of the biomaterial composi 
tion. For example, the TOSUs may comprise about 1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 wt % 
(or some range therebetween) of the biomaterial composi 
tion. 
In another aspect, filler(s) are combined with one or more 
TOSUs. The optional filler and optional TOSU is preferably 
selected from the group consisting of (1) crushed light initi 
ated SilMix (pre-polymerized SilMix); (2) DY5-yttria alu 
mino-silicate; 15.0 wt %YO, 5.0 wt % Al-O, and 80 wt % 
SiO2; (3) DY5 modified with 2-(3,4-epoxycyclohexyl)-ethyl 
trimethoxysilane (ECHE); (4) DY5 modified with 3-(gly 
cidyloxy)-propyl-trimethoxysilane (GPS); (5) DY5 modified 
with 3TOSU (3-(9,9-diethyl-1,5,7,11-tetraoxaspiro5.5un 
decan-3-yl)propyl)trimethoxysilane; (6) DY5 modified with 
1TOSU ((9,9-diethyl-1,5,7,1'-tetraoxaspiro5.5undecan-3 
yl)methyl)trimethoxysilane; (7) M12-barium boroalumino 
silicate; 54.5 wt % SiO, 5.9 wt % Al-O, 10.5 wt % BO, 
and 29.1 wt % BaC); (8) M12 modified with ECHE ethylcy 
clohexylepoxide; (9) M12 modified with 3TOSU (3-(9.9- 
diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)propyl)tri 
methoxysilane; (10) M12 modified with 1TOSU (9.9- 
diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)methyl) 
trimethoxysilane; (11) clays, montmorillonite plates of 
aspect ratio between about 100 to 300, surface modified with 
organic ammonium ions containing epoxy, hydroxyl, ether, 
ester, phosphate, allyl or vinyl functional groups, or silanes 
(trichloro, trimethoxy, triethoxy, dichloromethyl, 
dimethoxymethyl, diethoxymethyl, chlorodimethyl, meth 
oxydimethyl, or ethoxydimethyl) containing a pendant 
epoxy, hydroxyl, ether, ester, phosphate, allyl or vinyl func 
tional group; and (12) nanoparticles as spherical, nanofiber, 
nanowhisker, or nanorod—especially gamma aluminum, 
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hydroxyapatite, calcium phosphate, Zirconium, or titanium, 
with aspect ratio in the range of about 1 to 200, preferably 
between 1 and 20, neat or surface modified with organosi 
lanes (trichloro, trimethoxy, triethoxy, dichloromethyl, 
dimethoxymethyl, diethoxymethyl, chlorodimethyl, meth 
oxydimethyl, or ethoxydimethyl) containing a pendant 
epoxy, hydroxyl, ether, ester, phosphate, allyl or vinyl func 
tional group or Surface modified with organophosphates con 
taining a pendant epoxy, hydroxyl, ether, ester, allyl or vinyl 
functional group, including 1 TOSU, 3TOSU, or a TOSU 
phosphate surface active, ligand groups. 
The following examples are offered to aid in understanding 
the invention and are not to be construed as limiting the scope 
thereof. 
EXAMPLE1 
Preparation of Exemplary Bone Cement 
Compositions 
In this example, various biomaterials useful as bone 
cement compositions were prepared. All samples were pre 
pared at room temperature (about 20°C.) under yellow light 
(for the light-initiated systems and the dual chemical/light 
curing systems, but not the chemical curing systems) in order 
to prevent premature polymerization. The samples will be 
referred to as either neat resins (no filler) or filled resin (may 
include one or more fillers). 
Each of the bone cement compositions comprised two 
silorane monomers, bis(2-(3{7-Oxabicyclo[4.1.0]hepty1}) 
ethylmethylphenyl silane (PHEPSI) and 2,4,6,8-tetrakis(2- (7-Oxabicyclo4.1.0 heptan-3-yl)ethyl)-2,4,6,8-tetramethyl 
1.3.5.7.2,4,6,8-tetraoxatetra-silocane (CYGEP). Both 
PHEPSI and CYGEP were prepared using adapted proce 
dures and used at purities greater than 95.8% as determined 
by "H NMR spectroscopy. See Aoki, U.S. Pat. No. 6.255.428; 
Crivello, The Synthesis and Cationic Polymerization of Mul 
tifunctional Silicon-Containing Epoxy Monomers and Oligo 
mers, J. Polym. Sci. Part A: Polym. Chem.32 683-697 (1994). 
P1 comprises a chemical cure system comprising an organo 
metallic catalyst and an accelerator. P2 comprises a dual 
chemical/light cure system comprising and organometallic 
catalyst and a photoinitiation system. 
P1 comprises (A) co-monomer system SilMix (1:1 by 
weight of PHEPSI and CYGEP), between about 40 to 55 wt 
%; (B) photoacid p-(octyloxyphenyl)phenyliodonium 
hexafluoroantimonate, between about 0.05 to 0.20 wt %; (C) 
Lamoreaux's catalyst, between about 0.09 to 0.2 wt %; (D) 
filler DY5, between about 10 to 20 wt %; and (E) filler crushed 
Sil Mix, between about 25 to 50 wt %. The following table 
includes several exemplary bone cement compositions that 
were prepared. 
TABLE 3 
Exemplary P1 formulations 
SiMix Pre-polymerized 
Silorane Co-Monomer SiMix DYS PIH LMC 
OS466 O.3SOO O.1OOO O.OO14 O.OO20 
O.4000 O4SOO O.1472 O.OOO8 O.OO2O 
O.4000 O4SOO O.1472 O.OOO8 O.OO2O 
O.4000 O.3960 O.2OOO O.OO2O O.OO2O 
O.4722 O.3997 O.1247 O.OO17 O.OO17 
O4242 O4118 O.1618 O.OO11 O.OO11 
O4472 O.3SOO O.2OOO O.OO2O O.OOO8 
O.4000 O.3960 O.2OOO O.OO2O O.OO2O 















Exemplary P1 formulations 
SiMix Pre-polymerized 
Silorane Co-Monomer SiMix DYS PIH LMC 
O.S472 O3SOO O.1000 OOO2O O.OOO8 
O4972 O4(OOO O.1000 OOOO8 O.OO2O 
O.S478 O3SOO O.1000 OOOO8 OOO14 
O4483 O.3994 O.1494 OOO14 O.OO14 
O4(OOO O3984 O.2OOO O.OOO8 O.OOO8 
O4483 O.3994 O.1494 OOO14 O.OO14 
O4472 O3SOO O.2OOO O.OO2O O.OOO8 
O4960 O3SOO O.1SOO O.OO2O O.OO2O 
O4472 O3SOO O.2OOO O.OOO8 O.OO2O 
O5466 O3SOO O.1000 OOO14 O.OO20 
O4483 O.3994 O.1494 OOO14 O.OO14 
O4483 O.3994 O.1494 OOO14 O.OO14 
O446O O4SOO O.1000 OOO2O O.OO2O 
O4(OOO O4SOO O.1472 O.OO2O O.OOO8 
O4978 0.3747 O.1247 O.OO17 O.OO11 
O4484 O4SOO O.1000 OOOO8 O.OOO8 
O.S478 O3SOO O.1000 OOOO8 OOO14 
O4475 O4247 O.1247 O.OO17 O.OO14 
O4(OOO O3984 O.2OOO O.OOO8 O.OOO8 
O4984 O3SOO O.1500 OOOO8 O.OOO8 
O.S472 O3SOO O.1000 OOO2O O.OOO8 
O4472 O3SOO O.2OOO O.OOO8 O.OO2O 
O4(OOO O.3960 O.2OOO O.OO2O O.OO2O 
O446O O4SOO O.1000 OOO2O O.OO2O 
O.4722 0.3747 O.1497 O.OO17 O.OO17 
O4483 O.3994 O.1494 OOO14 O.OO14 
O4984 O3SOO O.1500 OOOO8 O.OOO8 
O4484 O4SOO O.1000 OOOO8 O.OOO8 
O4960 O3SOO O.1SOO O.OO2O O.OO2O 
O4484 0.3747 O.1747 O.OO11 O.OO11 
O4972 O4(OOO O.1000 OOOO8 O.OO2O 
P2 DY5 mod ECHE (“P2A) comprises (A) co-mono 
mer system Sil Mix (1:1 by weight of PHEPSI and CYGEP), 
between about 35 to 55 wt %, ’%; (B) Lamoreaux's catalyst, 
between about 0.3 to 0.8 wt %; (C) a light initiation system 
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo 
nium hexafluoroantimonate, about 1.0 wt % cam 
phorquinone, and about 0.15 wt % ethyl 4-dimethylami 
nobenzoate; and (D) a filler ECHE modified DY5, between 
about 45 to 65 wt %. 
P2 DY5 mod 3TOSU (“P2B) comprises (A) co-mono 
mer system SilMix (1:1 by wt of PHEPSI and CYGEP), 
between about 35 to 55 wt %; (B) Lamoreaux's catalyst, 
between about 0.3 to 0.8 wt %; (C) a light initiation system 
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo 
nium hexafluoroantimonate, about 1.0 wt % cam 
phorquinone, and about 0.15 wt % ethyl 4-dimethylami 
nobenzoate; and (D) a filler 3TOSU modified DY5, between 
about 45 to 65 wt %. 
P2 DY5 mod 1TOSU (“P2C) comprises (A) co-mono 
mer system SilMix (1:1 by wt of PHEPSI and CYGEP), 
between about 35 to 55 wt %; (B) Lamoreaux's catalyst, 
between about 0.3 to 0.8 wt %; (C) a light-initiation system 
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo 
nium hexafluoroantimonate, about 1.0 wt % cam 
phorquinone, and about 0.15 wt % ethyl 4-dimethylami 
nobenzoate; and (D) a filler 1TOSU modified DY5, between 
about 45 to 65 wt %. 
The components of the exemplary inventive formulations 
are mixed together in order to indicate polymerization. In a 
preferred aspect, all of the components except the Lamor 
eaux's catalyst are first mixed together in a Suitable mixing 
device (such as a mixing cup). The desired amount of Lam 
oreaux's catalyst is added and then the combined mixture is 
further mixed. 
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For comparative purposes, in some instances, the inventive 
formulations were compared to those of conventional 
PMMA-based Simplex P Bone Cement (Stryker Homedica 
Osteonics). The first powder component is a mixture of poly 
methyl methacrylate (PMMA) (15.0%), methyl methacry 
late-styrene-copolymer (75.0%), and barium sulfate (10.0%). 
The second component of Simplex P bone cement is a liquid 
monomer containing methyl methacrylate monomer 
(97.4%), N,N-dimethyl-p-toluidine (2.6%) and hydro 
quinone (7515 ppm). The two components are mixed at a ratio 
of 2 g powder to 1 mL liquid monomer to initiate the free 




The bone cement compositions of the present invention 
will be tested for polymerization stress. Two glass rods are 
placed 1 mm apart on the Bose mechanical testing instrument. 
Strain during testing will be held constant, less than 1.0 Lim 
deflection, during polymerization. The peak load during 
polymerization will be used to calculate polymerization 
10 
15 
stress as generally described in Eick et al., Properties of 25 
silorane-based dental resins and composites containing a 
stress-reducing monomer, Dent Mater 23(8) 1011-1017 
(2007), which is incorporated by reference. 
Maximum Exotherm Temperature 
Exotherm temperature was measured using a K-type ther 
mocouple (Omega, Stamford, Conn.) affixed to a glass slide 
and slightly bent so that the tip of the thermocouple was 
positioned in the center of an acetal resin (Delrin R) washer 
(McMaster-Carr, Aurora, Ohio), which was also affixed to the 
glass slide with lab tape. Each composite formulation (0.6 g) 
was mounded to completely cover the tip of the thermo 
couple. The sample was then irradiated (12 mm diameter tip, 
450 mW/cm (Cure Rite, Dentsply Caulk, Milford, Del.) at a 
distance of 3 mm) using a dental curing lamp (3M XL3000, 
St. Paul, Minn.) for two minutes. Specimens were inspected 
after testing, and results were excluded from further study if 
the tip contacted the glass slide or was not entirely covered 
with the composite. Temperature data were recorded using a 
data logger (OM-PLTC, Stamford, Conn.) at 1 Hz for 30 
minutes post-irradiation. Handling time was defined as the 
time between initiation and when the exotherm reached half 
of its peak temperature. 
Handling Properties/Handling Time 
The handling properties generally refer to the time from 
addition of catalyst or irradiation until one cannot manipulate 
the material. That is, handling time refers to the length of time 
the material can be manipulated between mixing and poly 
merization to allow for placement in the body. Bone cement 
consistently reaches dough time around 1.9 mm penetration 
(about 9 minutes post-mixing). Curing time occurs when 
penetration is 0.0 mm (about 15 minutes). 
Handling properties will be measured with a penetrometer. 
Timing will start as the monomer (0.75 g) is mixed and placed 
in an aluminum washer (12.7 mm diameter, 2.5 mm deep). 
Penetration measurements (mm) will be taken periodically 
with a mass of 49.2 g applied to the penetrometer cone for 5 
seconds. This test will provide viscosity, and curing, dough, 
and manipulation time. 
Flexural Strength and Modulus 
The bone cement compositions of the present invention 
will be tested for flexural strength. Flexural specimens (25 










(VitroCom, Mountain Lakes, N.J.) coated with silicone spray 
mold release (Mark V Laboratory, East Granby, Conn.) as per 
ISO specification 4049. A pipette was used to fill the molds 
with resin. The specimen was irradiated (12 mm diameter tip, 
450 mW/cm (Cure Rite, Dentsply Caulk, Milford, Del.) at a 
distance of 3 mm) using a dental curing lamp (XL3000; 3M, 
St. Paul, Minn.) for two minutes along the top surface at three 
consecutive regions for 40 seconds each, 40 seconds in a 
scanning motion along the bottom of the glass mold, and then 
the specimen was removed from the glass. The method of 
photoinitiating specimens and induction of any overlapping 
regions have been shown to not have an effect on flexural 
properties. The specimens were stored in phosphate buffered 
saline (PBS), at 23+1° C., for 24 hours, after which, the 
specimen was loaded, until fracture, at a displacement rate of 
3.7 mm/min in a four-point bend fixture with a support span 
of 20 mm on a BOSE mechanical tester (EnduraTEC ELF 
3300, Eden Prairie, Minn.). Specimens with visible surface 
flaws, bubbles, or undistributed filler particles were excluded 
from the study. The resulting stress-strain curve was used to 
determine flexural strength (O) and flexural modulus of elas 
ticity (E). The following two equations were used to calcu 
lated stress (Eq. 1) and strain (Eq2). The resulting stress-strain 
curve was used to determine flexural yield strength and flex 
ural modulus of elasticity 
loadX load span 
O -
specimen width x (specimen thickness) 
5.4X displacementX specimen thickness 
- - - -load span? 
Compressive Strength 
The bone cement compositions of the present invention 
will be tested for compressive strength. Cylindrical speci 
mens (6 mm diameterx12 mm height) were formed in a metal 
mold coated with silicone spray mold release as per ISO 
specification 4049. A pipette was used to fill the mold and 
composite formulations were either light-irradiated for 2 
minutes at each end of the cylinder for photoinitiated mate 
rials, or allowed to polymerize for 30 minutes for chemically 
initiated materials. The cylinders were then removed from the 
molds and stored in PBS, at 23+/-1° C., for 24 hours, after 
which specimens were loaded until fracture at a displacement 
rate of 20 mm/min between two smooth platens in compres 
sion. Specimens with visible surface flaws, bubbles, or undis 
tributed filler particles were excluded from the study. The 
resulting peak load prior to failure was used to calculate 
compressive strength. 
TABLE 4 
Range of properties for P1 and P2 (P2A. P2B. P2C). 
Desired ISO 5833 
P1 P2 properties Standard 
Polymerization stress s1.0 
(MPa) 
Exothermicity (C.) 25-30 26 - O.S s:45 s90 
Handling time (mins) 8-10 8-10 s20 3-15 
Intrusion (mm) e2 
Flexural modulus (GPa.) 15-17 2.2-3.5 e1.8 
Flexural strength (MPa) 22-33 25-60 eSO 
Compressive strength 68-77 ef) 
(MPa) 
Cytotoxicity (% cell death) 1796 s2O% 
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EXAMPLE 3 
Cytotoxicity on Neat Dual Cure SilMix 
In this example, the objective was to determine the bone 
cell growth on chemically cured silorane resins using a poly 
merization system containing acetic acid as a proton donor 
plus exposure to halogen lamp. The compositions are 
described in Table 5. Solid resin discs (9 mm diamx0.5 mm 
thick) (n=12) were yellow and transparent. Discs passed the 
GNT and were delivered in a closed plastic container. The 
discs were yellowish transparent and were used as received 
(no UV light sterilization as in previous experiments). Discs 
were placed into 48-well plate (n=4), pre-washed in growth 
media for 1 h at 35°C./5% CO. Then the wash media was 
replaced with 0.5 mL MLO-A5 cell suspension containing 
2x10 cells. After 24 hours and 48 hours in culture, cell 
viability was measured using the MTT assay and the number 
of live and dead cells was measured using the TBE assay. The 
results are summarized in Table 6 and FIG. 1. 
TABLE 5 





similar for all chemically cure resins, their decrease in cell 
numbers seem to be an effect of cell growth inhibition rather 
than cell death. Growth inhibition may have occurred because 
cells did not attach well to the polymer surfaces. 
EXAMPLE 4 
Cytotoxicity of Neat Chemically Initiated Silorane 
Using LMC 
In this example, the Lamoreaux's catalyst-cured resin (Sil 
Mix CC) was tested for in vitro biocompatibility and was 
found to be comparable to the light cure silorane resin (SilMix 
LC). The formulations investigated are shown in the follow 
ing Table 7. 
Compared to Light Cured Silorane 
Chem ID Bio ID SiMix AA PIH CPQ 
SM17-DVA DCA 3g 0.024 g 0.024 g 0.008 g 
SM17-DVB DCB 3g 0.048 g 0.048 g 0.016 g 
SM17-DVC DCC 3g 0.096 g 0.096 g 0.032 g 
SM17 PIHB Light initiated 3g 0 g 0.094g 
used as control 
0.031 g 0.005 g 
AA= acetic acid; PIH = p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate; CPQ = camphorquinone; 
EDMAB = ethyl p-dimethylaminobenzoate. 
TABLE 6 
Live and Dead Cell Numbers and Calculated Percent in the Trypan Blue Test. 
24h live cells 24h dead cells 48 h live cells 
ID # cells x 10 % it cells x 10 % it cells x 10 % 
control 26 - 1 89 3 - 1 11 519 89 
DCA 43 43 52 57 82 65 
DCB 93 68 4 + 1 32 93 66 
DCC 103 75 3 - 1 24 164 81 
PIH (light) 15 - 4 86 2 - O.S 14 24 6 89 
The MTT results indicate that dual cured resins (DCB and 
DCC) produced adherent cell viability similar (p-0.05) to the 
photoinitiated silorane resin PIH in 24 hours (FIG.1, panele) 
and 48 hours (FIG. 1, panel f) cultures. However, in the 
Trypan blue assay (Table 6), only the dual cured resin DCC 
produced live cell numbers (adherent and non adherent) simi 
lar (p-0.05) with the photoinitiated silorane resin PIH in 24 
hours (FIG.1, panela) and 48 hours (FIG.1, panelb) cultures. 
From the MIT and Trypan blue results, the dual cured resin 
DCC is more biocompatible than the others tested and was the 
most similar to the photoinitiated silorane PIH. Among the 
dual cured resins, the resin DCC contained more polymeriza 
tion system (about 7%) than the other two resins (DCB 3.6% 
and DCA 1.8%) which used decreasing amounts of acetic 
acid (Table 5). It is thought that with more initiator there is 
likely more polymerization. Therefore, there would be less 
monomer and more reacted polymer resulting in less toxicity. 
However, since the dead cells (as number and percent) appear 
# cells x 10' 
6 - 2 
3 - 2 
51 
4 + 1 












Chemically cured silorane (SilMix CC) formula compared 
to light cured silorane (SIMix LC 
PHEPSI 
CYGEP LMC EDMAB 
Polymer 1:1 (g) (g) PIH (g) CPQ (g) (g) 
SiMix LC is 3.00304 O.O940S O.O3130 OOO468 
control and light (95.85%) (3.005%) (0.99%) (0.153%) 
initiated 
SiMix CC 4.OO133 O.OO274 O.OOO148 
(99.89%) (0.07%) (0.04%) 
LMC = Lamoreaux catalyst; 
PIH = p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate; 
CPQ = camphorquinone; 
EDMAB = ethyl p-dimethylaminobenzoate 
Polymer discs were prepared from both photoinitiated 
(LC) and chemically initiated (CC) SilMix. The samples were 
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sterilized on the day of assay using two hour UV light expo 
Sure in a tissue culture laminar hood. Then, discs were placed 
into 48-well plate (n=3-4), pre-washed in growth media for 
one hour at 35° C./5% CO. The wash media was discarded 
and replaced with 2x10 MLO-A5 cells/0.5 mL. After 24 5 
hours and 48 hours of incubation, cell viability and prolifera 
tion was measured using the trypan blue method. Another set 
of discs was used for extraction of leachables by incubating 
the discs for 24 hours in culture media with serum. After 24 
hours, the extracts were transferred to a monolayer of MLO- 10 
A5 cells (seeded the day before). The cells were exposed to 
the extracts for 24 hours, after which the cell viability was 
measured using the MTT assay. Based on the trypan blue 
exclusion assay results, the number of live cells in the wells 
with the polymer Sil Mix LC and Sil Mix CC were less than 15 
(p<0.05) the control (plastic cell culture wells), while there 
was no significant difference in the number of dead cells. The 
percentage of live to dead cells with LC and CC SilMix was 
the same as the controls (FIG. 2) showing that the reduction in 
cell number was not due to toxicity but was due to reduced 20 
proliferation. This is most likely due to reduced adherence to 
the polymer Surface as bone cells have been shown to require 
an attachment surface to proliferate. This lack of cytotoxicity 
was confirmed in the MTT assay. The Formazan product in 
the presence of extracts from Sil Mix LC (OD=0.954) and 25 
Sil Mix CC (0.96+3) were similar to the controls (0.92+5). 
From these results, it is clear that the in vitro cytocompatibil 
ity of the chemical cure SilMix is comparable to the photo 
initiated SilMix in the 24 and 48 hour cultures with bone like 
MLO-A5 cells. 30 
EXAMPLE 5 
Stabilization of Fractured Excised Femur with 
Differently Cured Sil Mix Resin 35 
In this example, the stabilization effects of a dual chemical/ 
light cured composition of the present invention was com 
pared to that of a conventional light curing system. A halogen 
light (100W) at a distance of 18 inches was used to cure the 40 
system over a period of about 5 minutes. The dual cure system 
comprised (A) co-monomer system SilMix (1:1 by weight of 
PHEPSI and CYGEP), 93 wt %; (B) weak Bronstead acid— 
acetic acid, 3 wt %, (C) photoacid p-(octyloxyphenyl)phe 
nyliodonium hexafluoroantimonate, 3 wt %, and (D) photo- 45 
sensitizer, camphorquinone 1 wt %. For comparative 
purposes, a light cure system comprising 95.85 wt % SilMix, 
3 wt % PIH, 1 wt % camphorquinone, and 0.15 wt % EDMAB 
was used. 
More specifically, in this example, functional studies have 50 
been developed to determine the ability of filled SilMix to 
stabilize bone in animal models. Pilot testing has begun on 
extracted and in vivo rat femurs with a clean-cut fracture 
introduced with a circular saw. SilMix or control bone cement 
is applied around the bone creating a 1-mm wide by 1-2 mm 55 
thick band of composite material. The flexural strength of the 
stabilized bones is then determined using four-point bend 
testing. These initial studies have revealed that the more elas 
tic behavior of the SilMix is better suited to provide bone 
stability than the relatively brittlebone cement (Simplex(RP). 60 
Six mice were sacrificed by authorized personnel. The 
femora were then harvested from freshly sacrificed mice and 
stripped of Soft tissues. Femora were fractured using a hand 
held circular saw. The fractured bones were repositioned and 
stabilized with 50-70 uL of each SilMix resins around the 65 
fracture site (n=6/SilMix formulation). The resin was cured 
either using a halogen lamp for 5 minutes (dual initiation 
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SilMix) or a dental curing lamp 3 times for 20 seconds (pho 
toinitiated SilMix). The stabilized bones were stored in a 
humidified atmosphere for 24 hours, and then tested biome 
chanically. The data (FIG. 3) show that there is no difference 
between the photoinitiated and dual cured SilMix group. 
EXAMPLE 6 
Characterization of Flexure Strength and Modulus of 
Neat Bone Cement 
As discussed above, the flexural strength and flexural 
modulus results for the P1 system and P2 systems was inves 
tigated. The results are illustrated in panelsa and b of FIG. 4. 
More specifically, panel a of FIG. 4 illustrates the flexural 
strength while panelb of FIG. 4 illustrates the flexural modu 
lus of the P1 and P2 systems compared to a conventional 
PMMA system. P1 (aka BCM52) comprised 50 wt % Sil Mix, 
0.1 wt % PIH, 0.1 wt % Lamoreaux's catalyst, 35.8 wt % 
pre-polymerized crushed SilMix, and 14 wt % DY5 filler. P2 
comprised 39.45 wt % SilMix with a light initiation system 
(EDMAB 0.15 wt %: CQ 1 wt %; PIH;3 wit%; Sil Mix 95.85 
wt %), 0.56 wt % Lamoreaux's catalyst, and 59.99 wt % 
3TOSU modified DY5 filler. “P2 W/1TOSU-1’ and “P2 
w/1TOSU-2 were two separate beams comprising 39.7 wt % 
Sil Mix with a light initiation system (EDMAB 0.15 wt %; CQ 
1 wt %; PIH, 3 wt %; Sil Mix 95.85 wt %), 0.3 wt % Lamor 
eaux's catalyst, and 60.01 wt %1TOSU modified DY5 filler. 
In separate experiments, the flexural strength and flexural 
modulus of two different P1-type of systems (Table 8) was 
investigated, the results of which are shown in FIG. 4 (panels 
c and d) and Table 9. It will be appreciated that these inventive 
systems are filled systems containing Lamoreaux's catalyst. 
TABLE 8 
Exemplary Pll Systems 
% Pre 
Total % % % Polymerized % 
Sample (g) SiMix PIH LMC SiMix DYS 
BCMS1 3.17682 42.18 O.10 O.10 45.85 1177 
BCMS2 2.67889 49.95 O.10 O.10 35.85 14.00 
TABLE 9 
Flexural Strength/Modulus of Exemplary Pll Systems 
Flexural Test Modulus 
Strength (MPa. GPa. 
samples Mean St Dew Mean St Dew in Mold Storage 
BCMS1 22.26 2.78 1.58 O.O6 7 glass 24 hr? 
PBS 
BCMS2 25.77 1.53 1.63 O.O7 7 glass 24 hr? 
PBS 
In this example, the stress-strain curve for a neat dual 
chemical/light cure system having acetic acid was also deter 
mined as generally shown in panele of FIG. 4. The biomate 
rial composition comprised 93 wt % SilMix, 3 wt % acetic 
acid, 3 wt % PIH, and 1 wt % camphorquinone. The dual 
chemical/light cured silorane required about 5 minute's expo 
Sure to halogen light to polymerize. There was concern about 
the compatibility of the mechanical testing molds that were 
developed for chemical cured materials. The compression 
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cylinders are 1.2 cm long and 5 minute halogen light exposure 
results in polymerization throughout the specimen. 
Seven flexure beams were produced of a reasonable quality 
(still some small flaws, mostly towardends of beam where not 
directly affecting flexural testing). After 24 hours of dark 
storage at room temperature, these were loaded at a rate of 3.7 
mm/min as previously with bone cement. 
TABLE 10 
Flexural Strength - Dual Cured Silorane (unfilled). 
beam strength (MPa) strain modulus (MPa) 
1 41.3 7.3% 1693.7 
2 SO.4 8.1% 1908.1 
3 74.1 9.8% 2222.9 
4 57.5 8.3% 1724.0 
5 42.5 8.2% 1417.6 
6 55.6 6.7% 2627.7 
7 40.7 6.9% 1626.8 
Mean 51.7 7.9% 1888.7 
These values (Table 10) were comparable to previously 
tested bone cement values. However, bone cement gave a 
yield strength instead of maximum strength. The dual cured 
specimens show a brittle fracture (FIG. 4). 
EXAMPLE 7 
Exotherms of Neat Chemically Initiated SilMix 
(SM) 
In this example, the chemically cured composition com 
prised (A) co-monomer system SilMix (1:1 by weight of 
PHEPSI and CYGEP), 99.89 wt %; (B) photoacid p-(octy 
loxyphenyl)phenyliodonium hexafluoroantimonate, 0.04 wit 
%, and (C) organometallic catalyst, Lamoreaux's catalyst, 
0.07 wt %. As a control, the light initiated composition com 
prised (A) co-monomer system SilMix (1:1 by weight of 
PHEPSI and CYGEP), 95.85 wt %; and (B) light initiation 
system comprising 3.0 wt % p-(octyloxyphenyl)phenyliodo 
nium hexafluoroantimonate, about 1.0 wt % cam 
phorquinone, and about 0.15 wt % ethyl 4-dimethylami 
nobenzoate. 
Samples of approximately 120 mg were then placed on 
thermocouples. Thermocouples had been previously pre 
pared by taping a delrin washer on a glass slide onto which the 
tip of the thermocouple was taped. The tip of the thermo 
couple was centered approximately in the delrin washer. Pho 
toinitiated SM samples were also tested using a similar man 
ner. However, after mixing samples were placed in the delrin 
washer/thermocouple set-up and irradiated for two minutes 
with a dental curing lamp. Peak exotherm was collected from 
the plots as well as cure time, defined as the time from mixing 
to pass peak exotherm to reach half or max temperature 
(Table 11). Sample temperature plots are shown in FIG.5 for 
both the photo and chemical initiated SilMix. 
TABLE 11 
Maximum exotherm measurements for photoinitiated and chemically 
initiated silorane resins. 





51.4 (4.6) 9 














It was also observed that the polymerization time and heat 
generated is directly proportion to the speed of mixing as well 
of material. Thinner samples polymerize slower than larger 
samples. For example, 500 mg of material on glass slide 
polymerizes in 15 minutes (passes GNT); whereas, a 100 mg 
sample will take up to 45 minutes to polymerize. Also, the 
speed of mixing generates more heat and aids in the polymer 
ization reaction. The LMC catalyst was mixed in by hand. 
EXAMPLE 8 
Filled Chemically Initiated Silorane Exotherm 
In this example, two formulations were tested (Table 12, 
FIG. 6). Bone cement mimics (BCM) 1/2 and 3/4 had the 
same composition but were derived from different batches of 
formulation. Bone cement mimic 5/6 contained a lower 
amount of PIH and LMC. Due to the thinness of the samples, 
it took approximately 30 minutes to complete cure to hard 
ness (pass the one-1b GNT). 
TABLE 12 
Cure time of three sillorane bone cement mimic formulations. 
Curing 
% % % % % Max Time 
Sample SM PIH LMC CSM DY5 (° C.) (sec) 
BCM1 34.25 O.15 O.15 SS.84 9.61 34.9 128 
BCM2 34.25 O.15 O.15 SS.84 9.61 35.3 156 
BCM3 34.25 O.15 O.15 SS.84 9.61 29.5 247 
BCM4 34.25 O.15 O.15 SS.84 9.61 32.7 243 
BCMS 34.27 O.10 O.11 55.91 9.61 27.0 88 
BCM 6 34.27 O.10 O.11 S5.91 9.61 27.0 96 
SM-SilMix; PIH phenyl iodonium salt; LMC Lamoreaux's catalyst; CSM-crushed 
SM (polymerized); DY5–yttrium silicate glass filler (unmodified) 
Overall, exotherm temperatures of the chemically cured 
silorane bone cement mimics were well below 45° C. limit 
(FIG. 7). There was some variability, likely due to difference 
in mixing techniques, time to add the LMC, etc. Lower con 
centrations of LMC catalyst resulted in a lower peak exo 
therm and somewhat of a double peak in temperature. These 
results were repeated, but only with two samples. Due to the 
narrow range in temperatures (about 10°C.), the resolution of 
our current thermocouple is inadequate (resulting in digitized 
plots). Need to identify alternate temperature recording 
device (RTD, thermistor, etc.) with greater resolution. 
PROPHETIC EXAMPLE 
It will be appreciated that biocompatibility is an important 
property for any biomaterial compositions of the present 
invention. In addition to the MLO-A5 cell lines, the biocom 
patibility of the compositions of the present invention can be 
assessed using, for example, MSCs (mesenchymal stem cells 
from bone marrow), L929 (fibroblast like cells), and HUVEC 
(human umbilical vein endothelial cells). Further, to deter 
mine the potential of the silorane compositions to induce 
mineralization as another measure of its biocompatibility 
with bone, differentiation assays, such as alkaline-phos 
phatase, and mineralization assays, Such as alizarin red and 
von Kossa staining, may be performed on the MLO-A5 cell 
line. These tests will determine the effect of the polymer on 
the ability of cells to proliferate, differentiate, and form min 
eralized matrix. 
Small Animal (Rat) Model: Pull-out strength ex vivo: 
These studies will be conducted according to published meth 
ods which have been used as an in vivo model for implants. 
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Male Sprague-Dawley rats (approximately 6 months old) will 
be sacrificed and kept in-80°C. freezer. The femora will be 
excised. A 2 mm hole will be drilled into the intercondylar 
notch with a Dremel drill bit to penetrate the subchondral 
cortical bone and gain access to the femoral intramedullary 
canal. The marrow cavity will be disrupted by inserting a 
threaded hand drill proximally through the entirelength of the 
diaphysis to approximately the level of the lesser trochanter. 
A guide implant will be placed into the ablated cavity to 
ensure that the canal will be an appropriate size to accommo 
date the definitive implant. The cavity will then be flushed 
with 10 mL of sterile saline for removal of loose marrow 
contents. Following irrigation, bone cement (chemically 
cured silorane and fillers (bone cement mimic) or commercial 
bone cement) will be introduced into the intramedullary canal 
with a root canal filler and then a titanium implant, 22 mm 
long and 1.5 mm diameter, will be implanted in a retrograde 
manner. The femora implanted with titanium rods fixed with 
bone cement mimic or commercial bone cement will be kept 
24 hours and tested biomechanically. The 2-4 mm of distal 
rod (implant) will be exposed; proximal half of femur will be 
embedded in dental acrylic in a holder. The holder is a lower 
part of a 15 mL centrifuge tube which is cut at mark-line 3 mL 
and can be filled 3 g of dental acrylic and is attached an eye 
hook at bottom. The exposed implant will be gripped with a 
drill chuck and Shooks will be placed at lower end of the 
specimen to keep coaxial alignment of the implant with the 
direction of force. The pullout test will be conducted at a 
displacement rate of 0.25 mm/min to failure with the force 
(N). The values will be calculated by dividing the force at the 
point of failure by the surface area of the implant in the femur. 
This result will determine if the silorane based bone cement 
provides adequate mechanical Support. 
Osteointegration of the silorane bone cement in vivo: After 
ex vivo testing, the osseointegration with the silorane bone 
cement or PMMA bone cement will be assessed. The general 
biological response, including inflammation and bone min 
eralization, must also be characterized for the silorane bone 
cements. The samples will be split into two parts: pull-out 
strength and histological analysis. 
Implant Placement: Male Sprague-Dawley rats (approxi 
mately 6 months old) will be placed under general anesthesia 
via isofluorane inhalation (3-4% for induction), ketamine/ 
dex-medetomidine (75/0.5 mg/kg body weight; IP) for main 
tenance. The animal will be weighed and the both legs will be 
shaved with a standard clipper and disinfected with povidone/ 
iodine Solution. Animals will be placed on a warming pad 
during Surgery as provided in the animal facility (recirculat 
ing water heating pad). All procedures will be performed 
under aseptic conditions. A 1 cm lateral parapatellar incision 
will be made to expose the knee joint. The patella will be 
retracted medially with the knee extended. The knee will be 
slowly flexed to expose the intercondylar notch. A 2 mm hole 
will be drilled into the intercondylar notch with a Dremel drill 
bit to penetrate the subchondral cortical bone and gain access 
to the femoral intramedullary canal. The marrow cavity will 
be disrupted by inserting a threaded hand drill proximally 
through the entire length of the diaphysis to approximately 
the level of the lesser trochanter. A guide implant will be 
placed into the ablated cavity to ensure that the canal will be 
an appropriate size to accommodate the definitive implant. 
The cavity will then be flushed with 10 mL of sterilesaline for 
removal of loose marrow contents. Following irrigation, bone 
cement (chemically cured silorane and fillers or commercial 
bone cement) will be introduced into the intramedullary 
canal, and then a titanium implant, 22 mm long and 1.5 mm 













sule and skin will be sutured with 4-0 nylon. Buprenex, 0.01 
0.05 mg/kg and Atipamezole, 0.1-1 mg/kg will be adminis 
tered intraperitoneally to the rat immediately post operation. 
The animal will be allowed to fully recover in a separate cage 
on the warming pad and will be allowed activity ad libitum. 
Post-op Analysis: The inflammatory response of incision 
and movement of operated limb will be monitored every day. 
Microcomputed tomography (MicroCT) and X-ray will be 
taken at weeks 1, 4, and 8 weeks post Surgery. Animals will be 
euthanized by CO asphyxiation at 1 (to examine for any 
inflammatory reaction) and 8 weeks (to examine for osseoin 
tegration) post Surgery. The femurs for mechanical testing 
will be harvested, denuded of soft tissue, and frozen at -20° 
C. The procedure of mechanical test could be seen above. The 
femurs for histology will be placed in 10% neutral buffered 
formalin. 
Tissue Preparation, Histology, and Histomorphometry: 
After placement and sacrifice, bones will be fixed in neutral 
buffered formalin, decalcified and embedded for frozen sec 
tions by standard techniques. Serial sections will be cut and 
stained with Hematoxylin and Eosin (H&E) or Goldner's 
trichrome using standard techniques. Staining for both TRAP 
and alkaline phosphatase can be performed. Undecalcified 
methacrylate embedded sections will also be stained by the 
Von Kossa procedure as described previously for determina 
tion of the mineralized bone volume by histomorphometry. 
Histomorphometric Analysis: Histomorphometric analy 
sis will be performed on long bones using a Nikon E800 
microscope with live video image capabilities that is inter 
faced with the Osteomeasure bone histomorphometry soft 
ware. The parameters to be measured from H&E and/or Gold 
ner's trichrome stained sections include trabecular and 
cortical bone Volume, osteoid seam thickness, and osteoblast 
numbers per mm bone surface. TRAP stained sections will be 
used for determination of the number of osteoclasts per mm 
bone surface. Von Kossa stained sections will be used to 
measure the volume of mineralized bone which will be 
expressed as a percentage of the total bone Volume (i.e., 
including osteoid). Three non-consecutive sections (100 um 
apart) from each specimen will be used for the histomorpho 
metricanalyses described above and these measurements will 
be performed by an individual who is without knowledge of 
the sample identities. Values will be expressed as the 
meantstandard error. Examination for wear debris particles 
in the surrounding tissue will be performed. 
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From the foregoing it will be seen that this invention is one 
well adapted to attain all ends and objectives herein-above set 
forth, together with the other advantages which are obvious 
and which are inherent to the invention. Since many possible 
embodiments may be made of the invention without depart 
ing from the scope thereof, it is to be understood that all 
matters herein set forth or shown in the accompanying figures 
are to be interpreted as illustrative, and not in a limiting sense. 
While specific embodiments have been shown and discussed, 
various modifications may of course be made, and the inven 
tion is not limited to the specific forms or arrangement of parts 
and steps described herein, except insofar as Such limitations 
are included in the following claims. Further, it will be under 
stood that certain features and subcombinations are of utility 
and may be employed without reference to other features and 
subcombinations. This is contemplated by and is within the 
Scope of the claims. 
We claim: 
1. A biomaterial composition comprising: 
a polymerizable silorane monomer, and 
a curing system selected from the group consisting of a 
chemical curing system and a dual chemical/light curing 
system, 
wherein the curing system comprises a rhodium-based or 
platinum-based organometallic catalyst, and wherein 
said silorane monomer comprises a mixture of 2.4.6.8- 
tetramethyl-2,4,6,8-tetrakis-2-(7-Oxabicyclo4.1.0 
hept-3-yl)ethyl-1,3,5,7-tetraoxa-2,4,6,8-tetrasilacy 
clooxtane (CYGEP) and methylbis 2-(7-Oxabicyclo 
4.1.0]hept-3-yl)ethylphenylsilane (PHEPSI). 
2. The biomaterial composition of claim 1 wherein said 
curing system comprises an organometallic catalyst selected 
from the group consisting of Lamoreaux's catalyst, Wilkin 
son’s catalysts, Speier's catalyst, and Karstedt's catalyst, or 
mixtures thereof. 
3. The biomaterial composition of claim 1 wherein said 













4. The biomaterial composition of claim 3, wherein said 
photoacid is a phenyliodonium compound. 
5. The biomaterial composition of claim 4 wherein said 
photoacid is selected from the group consisting of (4-n-octy 
loxyphenyl)phenyliodonium hexafluoroantimonate, 4-(2- 
hydroxy-tetradecyloxyphenyl)phenyliodonium hexafluoro 
antimonate, 4-1-methylethyl)-phenyl(4-methylphenyl) 
iodonium tetrakis(pentafluorophenyl)borate(1-), and 
combinations thereof. 
6. The biomaterial composition of claim 1 wherein said 
curing system is a dual chemical/light curing system, wherein 
said dual chemical/light curing system additionally com 
prises an acid selected from the group consisting of a Bron 
sted acid, Lewis acid, and a Superacid, and mixtures thereof. 
7. The biomaterial composition of claim 1 wherein said 
curing system is a dual chemical/light curing system addi 
tionally comprises an acid selected from the group consisting 
of acetic acid, phosphoric acid, Sulfuric acid, hydrobromic 
acid, hydroiodic acid, trichloroacetic acid, trifluoroacetic 
acid, p-toluenesulfonic acid, boron trifluoride, aluminium 
chloride, tin (IV) chloride, titanium chloride, pentafluoro 
proprionic acid, triflic acid, hexafluorophosphoric acid, ethyl 
triflate, potassium t-butoxide, and mixtures thereof. 
8. The biomaterial composition of claim 7 wherein said 
dual chemical/light curing system further comprises a photo 
sensitizer. 
9. The biomaterial composition of claim 8 wherein said 
photosensitizer is a diketone. 
10. The biomaterial composition of claim 7 wherein said 
dual chemical/light curing system further comprises an elec 
tron donor compound in which said electron donor is a Sub 
stituted amine. 
11. The biomaterial composition of claim 7 wherein said 
dual chemical/light curing system comprises acetic acid, 
p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate, 
and camphorquinone. 
12. The biomaterial composition of claim 11 further com 
prising a filler. 
13. The biomaterial composition of claim 12 further com 
prising a tetraoxaspiro5.5undecane. 
14. The biomaterial composition of claim 1 wherein said 
curing system is a dual chemical/light curing system, wherein 
said dual chemical/light curing system comprises a rhodium 
or platinum-based organometallic catalyst and a light initia 
tion system having a photoacid, photosensitizer, and an elec 
tron donor. 
15. The biomaterial composition of claim 14 wherein 
said organometallic catalyst is selected from the group 
consisting of Lamoreaux's catalyst, Wilkinson's cata 
lysts, Speier's catalyst, and Karstedt's catalyst; 
said photoacid is a phenyliodonium compound; 
said photosensitizer is a diketone; and 
said electron donor is a Substituted amine. 
16. The biomaterial composition of claim 14 wherein 
said organometallic catalyst comprises Lamoreaux's cata 
lyst; 
said photoacid comprises p-(octyloxyphenyl)phenyliodo 
nium hexafluoroantimonate; 
said photosensitizer comprises camphorquinone; and 
said electron donor comprises ethyl p-dimethylaminoben 
ZOate. 
17. The biomaterial composition of claim 16 further com 
prising a filler. 
18. The biomaterial composition of claim 17 further com 
prising a tetraoxaspiro5.5undecane. 
19. The biomaterial composition of claim 1 further com 
prising one or more tetraoxaspiro5.5undecanes. 
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20. The biomaterial composition of claim 19, wherein said 
tetraoxaspiro5.5undecane is selected from the group con 
sisting of a 2.4.8.10-tetraoxaspiro5.5undecane or a 1.5.7. 
11- tetraoxaspiro5.5undecane. 
21. The biomaterial composition of claim 19 wherein said 
tetraoxaspiro5.5undecane is selected from Formulas A1 
and A2 
R O O R3 
six X y O 
O O 
R1 O O R3 
six X). O O 
wherein RandR are independently is alkyl, aryl, aralkyl, 
or hydrogen; and 
wherein R and Rare independently alkenoxy, alkenoxy 
alkyl, or silicon-containing moiety selected from alkyl 
silyl, arylsilyl, arylalkylsilyl, alloxysilyl, aryloxysilyl, 
arylalkoxysilyl, alkylsiloxy, arylsiloxy, arylalkylsiloxy, 
alkoxysiloxy, aryloxysiloxy, arylalkoxysiloxy, alkylsi 
lylalkyl, arylsilylalkyl, arylalkysilylalkyl, alkoxysilyla 
lkyl, aryloxysilylalkyl, arylalkoxysilylalkyl, alkylsi 
loxyalkyl, arylsiloxyalkyl, arylalkylsiloxyalkyl, 
alkoxysiloxyalkyl, aryloxysiloxyalkyl, arylalkoxysi 
loxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, arylalkylsi 
lylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxy aryla 
lkyloxysilylalkoxy, alkylsiloxyalkoxy, 
arylsiloxyalkoxy, arylalkylsiloxyalkoxy, alkoxysiloxy 
alkoxy, aryloxysiloxyalkoxy, and arylalkoxysiloxy 
alkoxy. 
22. The biomaterial composition of claim 19, wherein said 
tetraoxaspiro5.5undecane is selected from the group con 
sisting of 3,9-diethyl-3.9-bis(allyloxymethyl)-1.5.7.11-tet 
raoxaspiro5.5undecane (DEBAOM-1,5,7,11-TOSU); 3.9- 
bis(3-trimethylsilylpropyl)-1.5.7.11-tetraoxaspiro5.5 



















methyl 2-(7-Oxabicyclo[4.1.0 hept-3-yl)ethyl-pheynl3 
(3.9.9-triethyl-1.5.7.11-tetraoxaspiro5.5undec-3-yl 
methoxy)propylsilane (MOB-HEP-TETOSU-MOPS). 
23. The biomaterial composition of claim 1 further com 
prising a filler. 
24. The biomaterial composition of claim 1 further com 
prising a pre-polymerized polymer derived from said poly 
merizable silorane monomer. 
25. The biomaterial composition of claim 1 comprising 
about 30 to 60 wt % silorane monomers; about 1 to 50 wt % 
of a pre-polymerized polymer derived from the silorane 
monomers; and about 0.05 to 5 wt % of the chemical curing 
system or dual chemical/light curing system, and wherein 
said curing system comprises acetic acid or Lamoreaux's 
catalyst. 
26. The biomaterial composition of claim 25 further com 
prising about 5 to 50 wt % of a filler. 
27. The biomaterial composition of claim 1 wherein said 
composition after polymerization exhibits a peak exotherm 
below about 30 °C. 
28. The biomaterial composition of claim 1 wherein said 
composition after polymerization exhibits a flexural strength 
of about 22 to 50 MPa. 
29. The biomaterial composition of claim 1 wherein said 
composition after polymerization exhibits a flexural modulus 
about 1.5 to 3.5 GPa. 
30. The biomaterial composition of claim 1 further com 
prising a heat-sensitive antimicrobial or growth factor that is 
Stable at about 25 to 30 °C. 
31. The biomaterial composition of claim 1 further com 
prising a growth factor selected from the group consisting of 
TGFB1, TGFB2, TGFB3, BMP-2, BMP-3, BMP-4, BMP-5, 
BMP-6, BMP-7, BMP-8, BMP-9, CDMP-1, CDMP-2, or 
CDMP-3. 
